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RIASSUNTO 
Introduzione. La fibrillazione atriale è l’aritmia cardiaca più comune, caratterizzata da un ritmo 
cardiaco irregolare, spesso ad alta frequenza, e associato alla formazione di trombi in atrio e auricola sinistra 
che possono causare l’ictus ischemico cardioembolico. La terapia anticoagulante orale ha dimostrato di 
ridurre l’incidenza di ictus ischemico in questI pazienti di circa due terzi, alle spese però di un’aumentata 
incidenza dei sanguinamenti. Nell’anziano la fibrillazione atriale è particolarmente frequente ma il suo 
trattamento presenta delle difficoltà: infatti, sebbene il rischio ischemico aumenti con l’età, anche il rischio 
emorragico è maggiore. ln questi pazienti il medico spesso preferisce non prescrivere o interrompere la 
terapia anticoagulante orale nel timore di complicanze. Il paziente anziano, inoltre, può essere portatore di 
più patologie, assumere diversi farmaci con potenziale rischio di interazioni farmacologiche e presentare una 
ridotta aderenza alla assunzione della terapia.  
Scopo della tesi.  Valutare l’impatto dell’anticoagulazione nel paziente anziano, con focus nel 
sottogruppo di pazienti con età  80 anni, che raramente vengono reclutati nei grandi trial clinici. 
VENPAF. Abbiamo inizialmente condotto uno studio retrospettivo “inception cohort” includendo 
tutti i pazienti con età  80 anni in terapia con warfarin presso il locale Centro Trombosi (studio VENPAF). 
Dall’analisi è emersa un’incidenza di emorragie maggiori molto alta, che tende ad aumentare sensibilmente 
sopra gli 85 anni di età; nonostante ciò, il beneficio clinico netto della terapia appare comunque mantenuto, 
in quanto l’incidenza calcolata di trombo-embolismo in assenza di anticoagulazione è risultata maggiore, in 
entrambe le classi di età, rispetto all’incidenza osservata di emorragie maggiori.  
Circa il 20% dei pazienti inclusi ha sospeso la terapia e questo è stato principalmente dovuto ad una 
decisione del medico di medicina generale o dello specialista; le ragioni addotte per la sospensione sono 
state la scarsa aspettativa di vita, la fragilità del paziente e l’eccessivo rischio emorragico. Abbiamo però 
constatato che la sospensione della terapia non era associata ad un miglioramento della prognosi ma anzi 
questi pazienti erano gravati da alti tassi di mortalità, eventi ischemici ed emorragici. 
Restringendo l’analisi ai pazienti che avevano sperimentato un evento emorragico in corso di terapia 
anticoagulante, abbiamo potuto evidenziare come l’incidenza cumulativa di eventi ischemici ed emorragici 
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era significativamente più alta nei pazienti che dopo tale evento sospendevano la terapia rispetto a quelli che 
la riprendevano.  
 Studio caso-controllo. Per analizzare i fattori di rischio associati allo sviluppo di emorragia cerebrale 
in warfarin, abbiamo eseguito uno studio caso-controllo includendo tutti i pazienti seguiti per fibrillazione 
atriale presso il nostro Centro Trombosi. Abbiamo confrontato 51 pazienti con emorragia intracranica con 
204 pazienti di controllo, appaiati per età, sesso ed esposizione alla terapia. Nessuna variabile analizzata è 
risultata associata allo sviluppo dell’emorragia. Abbiamo inoltre valutato il rischio emorragico per ogni 
paziente usando gli score HAS-BLED, ATRIA e ORBIT; tali score hanno presentato una capacità predittiva nei 
confronti dell’emorragia intracranica particolarmente scarsa o nulla (“c-statistic” minore 0.56 per tutti gli 
score utilizzati). 
 Registro Regione Veneto. Dallo studio VENPAF e dallo studio caso-controllo è emersa da una parte 
una forte tendenza al sanguinamento intracranico nel paziente anziano, dall’ altra l’impossibilità di 
individuare specifici fattori predittivi di tale sanguinamento. È quindi con grande interesse che abbiamo 
guardato all’utilizzo clinico dei nuovi anticoagulanti orali (NAO), farmaci che dagli studi registrativi sembrano 
essere in grado di dimezzare questa grave complicanza rispetto al warfarin. Analizzando i dati della Regione 
Veneto attraverso il registro regionale delle prescrizioni farmacologiche, delle esenzioni e delle diagnosi di 
dimissione dai reparti, abbiamo potuto selezionare i pazienti che iniziavano una terapia anticoagulante orale 
perché affetti da fibrillazione atriale non valvolare. In confronto a warfarin, i NAO si sono dimostrati 
ugualmente efficaci e sicuri.  Si è rilevata comunque una netta riduzione delle emorragie intracraniche e una 
lieve riduzione della mortalità rispetto alla terapia convenzionale, nonostante l’ottima qualità 
dell’anticoagulazione con warfarin raggiunta grazie ai centri trombosi veneti. In particolare, abbiamo 
riscontrato che nel Veneto i pazienti in terapia con NAO sono in media più anziani e a più alto rischio 
ischemico rispetto ai pazienti trattati con warfarin. 
 Abbiamo infine analizzato la popolazione di età 80 anni e riscontrato un deciso aumento delle 
emorragie gastrointestinali, soprattutto dal tratto inferiore, nei pazienti in terapia con NAO. Tale incremento, 
però, non ha modificato il profilo di sicurezza di questi farmaci, che presentano comunque un rischio 
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complessivo di emorragie maggiori e di ictus ischemici sovrapponibili al warfarin, con riduzione del rischio di 
emorragie intracraniche.   
 Conclusioni. Il presente lavoro di ricerca ha cercato di esplorare gli effetti della terapia anticoagulante 
nel paziente grande anziano con 80 anni o più. Dall’insieme degli studi condotti è stato possibile concludere 
che, nonostante l’elevato rischio di emorragia, il beneficio clinico per la prevenzione dell’ictus è a favore 
dell’uso di questi farmaci; andando infatti a considerare i pazienti che sospendevano il farmaco, abbiamo 
constatato una prognosi peggiore rispetto ai pazienti che rimanevano in terapia. Una parte non trascurabile 
delle emorragie in warfarin è dovuta ai sanguinamenti intracranici che sono spesso fatali o gravemente 
invalidanti; dai nostri dati tali eventi sono più frequenti nell’anziano e non sono prevedibili dai comuni fattori 
di rischio cardiovascolare, né da una buona qualità dell’anticoagulazione. I NAO sembrano invece mantenere 
anche nell’anziano un rischio di emorragie intracraniche inferiore al warfarin, nonostante un significativo 
aumento del rischio di emorragie gastrointestinali. Nel complesso, quindi, i nostri dati confermano i NAO 
come la terapia anticoagulante da preferire nella fibrillazione atriale non valvolare anche nel paziente molto 
anziano.    
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ABSTRACT 
Introduction. Atrial fibrillation is the most common cardiac arrhythmia, characterized by irregular heart 
rhythm and associated with left atrial and left appendage thrombi formation that may cause ischemic stroke. 
Oral anticoagulant therapy has been shown to reduce the incidence of ischemic stroke in these patients by 
about two thirds, at the expense of an increase in bleeding. In the elderly, atrial fibrillation is particularly 
frequent, but anticoagulant therapy often encounter several issues: in fact, although ischemic risk increases 
with age, haemorrhagic risk is also high and often doctors prefers not to prescribe or discontinue oral 
anticoagulant therapy in fear of complications. The elderly patient, moreover, is often affected by multiple 
diseases, takes several drugs with potential risk of interactions and may have lower adherence to therapy. 
Aim. To evaluate the impact of anticoagulation in the elderly patient, focusing on the subgroup of very 
elderly patients (i.e.  80 years of age) who are often not included in major clinical trials. 
VENPAF. We initially conducted a retrospective "inception cohort" study involving all patients  80 years 
of age referred to the local Thrombosis Centre to start anticoagulant therapy with warfarin for atrial 
fibrillation (VENPAF study). From data analysis, we found that major haemorrhages rate is very high and 
tends to increase considerably over 85 years of age. Nevertheless, net clinical benefit appears to be 
maintained, as the calculated incidence of thromboembolism in the absence of anticoagulant therapy was 
higher in both age classes compared to the observed incidence of major haemorrhages. 
About 20% of these patients had discontinued warfarin and this was often decided by the general 
practitioner or the specialist; main reasons for discontinuation were low life expectancy, fragility and 
excessive haemorrhagic risk. We found that therapy discontinuation was not associated with an 
improvement in prognosis, but indeed these patients faced high rates of mortality, ischemic and 
haemorrhagic events, regardless of persistence or discontinuation of anticoagulant therapy. 
Analysing only patients who experienced a major bleeding event during anticoagulant therapy, we could 
highlight how the cumulative incidence of ischemic and haemorrhagic events was significantly higher in 
patients who suspended therapy than those who resumed it after the index event. 
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Case-control study. A case-control study was set to analyse which factors may possibly be associated 
with the development of intracranial haemorrhage with warfarin (the most serious complication of oral 
anticoagulant therapy). All patients followed by our Thrombosis Centre who developed intracranial bleeding 
in anticoagulant therapy were included; control group was created from anticoagulated patients paired for 
age, sex, and exposure to therapy in a 1:4 ratio. No variable was associated with the development of bleeding. 
We also could evaluate ischemic risk for each patient using HAS-BLED, ATRIA and ORBIT haemorrhage scores; 
these scores showed a predisposing capacity for particularly poor intracranial haemorrhage (c-statistic 
around 0.55 for all three scores). 
Veneto Region Registry. After the analysis of cerebral bleedings during warfarin therapy, we focused on 
the use of non-vitamin K oral anticoagulants (NOAC), which demonstrated to halve cerebral bleeding as 
compared with warfarin in clinical trials. Using Veneto Region registries of pharmacological prescriptions, 
exemptions, and department discharge diagnoses, we were able to select patients who started oral 
anticoagulant therapy because of non-valvular atrial fibrillation and compared patients who started warfarin 
therapy versus those who started a NOAC. Results were broadly consistent with the literature, with similar 
efficacy and safety but a sharp reduction in intracranial bleedings and a mild reduction in mortality with 
NOAC, despite the good quality of warfarin anticoagulation achieved thanks to the thrombosis centers of our 
regions. Moreover, we found that patients treated with NOAC in Veneto region are on average older and at 
higher ischemic risk than patients treated with warfarin. 
Finally, we analysed the subset of patients ≥80 years old and found a marked increase in gastrointestinal 
bleeding, especially from the lower tract, in patients treated with NOAC. However, ischemic stroke and total 
major bleedings rates were similar among the two groups and NOAC patients showed a lower risk of 
intracranial haemorrhage. 
Conclusions. The present work analysed the effects of anticoagulant therapy in elderly patients with 80 
years or more. Based on the different studies we conducted, it was possible to conclude that, despite the 
high risk of haemorrhage, clinical benefit for the prevention of stroke is in favour for the use of these drugs 
in this subset of patients. In fact, patients who suspended anticoagulant treatment had a worse prognosis 
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than patients who persisted. Intracranial hemorrhage is the most fearful side effect of anticoagulant 
treatment, being related to very high rates of mortality and disability; from our findings, these events are 
more frequent in the elderly and are not predictable by common cardiovascular risk factors or good 
anticoagulation quality. Data on NOAC users, on the other hand, seem to confirm that the risk of intracranial 
bleeding is inferior to warfarin even in the very elderly, despite a significant increase in the risk of 
gastrointestinal haemorrhage. Overall, therefore, our data confirms NOAC as the preferred anticoagulant 
therapy in very elderly patients with non-valvular atrial fibrillation. 
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1. INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia that has the following 
electrocardiographic characteristics:  
- The RR intervals follow no repetitive pattern. 
- there are no distinct P waves, although some electrical activity suggestive of P waves may be seen in 
some leads. 
- even when an atrial cycle length can be defined, it is not regular and often less than 200 milliseconds  
AF has been classified according to its duration and characteristics as: paroxysmal (i.e. self-terminating or 
intermittent), persistent (i.e. that fails to self-terminate within seven days, often requiring pharmacologic or 
electrical cardioversion), long-standing persistent (i.e. lasted for more than 12 months) and permanent (i.e. 
when the arrhythmia is accepted with no further attempts to restore sinus rhythm).  
1.1 Atrial Fibrillation: epidemiology and physiopathology  
AF is a global health care problem with evidence suggesting an increasing prevalence and incidence 
world.1 A systematic review of worldwide population-based studies estimated that the number of individuals 
with AF in 2010 was 33.5 million. 
Prevalence. The prevalence of AF depends upon population characteristics, with differences apparent due 
to age, sex, race, geography, and time period.  Prevalence is also influenced by the duration, sensitivity, and 
specificity of screening techniques. 
- Age: AF is uncommon in infants and children and when present, almost always occurs in association 
with structural heart disease. Healthy young adults are also at low risk. The prevalence of AF 
increases with age2 with a prevalence of more than 10% in patients ≥80 years of age (figure 1.1). 
General prevalence of AF has been recently estimated in Germany as 2.132% 3 
- Sex: prevalence is slightly higher in men than women, a difference seen in every age group. In 
Germany 55.5% of people affected by NVAF is male. 3 
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- Race: whites are generally considered at higher risk of developing AF. A study evaluating the 
relationship between race and incident AF found that, compared with Whites, Blacks (hazard ratio 
[HR] 0.84), Hispanics (HR 0.78), and Asians (HR 0.78) each had a lower AF risk after adjustment. 4 
- Geography: Age-adjusted prevalence rate was highest in North America (700 to 775 per 100,000 
population) and lowest in Japan, China and South Korea (250 to 400 per 100,000 population). 1  
Figure 1.1 prevalence of AF by age and gender2 
 
- Time period: AF prevalence in the population is increasing. In a community-based study of 1.4 million 
patients in England and Wales, the age-standardized prevalence of AF between 1994 and 1998 
increased by 22 and 14 percent in men and women, respectively.5  In the ATRIA study, it was 
estimated that 2.3 million adults in the United States had AF in 1996 and 1997, and that this will 
increase to 5.6 million by the year 2050, with more than 50 percent being more than 80 years of age.2 
Incidence. Incidence of AF, similar to the prevalence, increases with advancing age. 6 In a longitudinal 
study in which 3983 male Air Force recruits were followed for 44 years, 7.5 percent developed AF.7 The risk 
increased with advancing age (from 0.5 per 1000 person-years before age 50 to 9.7 per 1000 person years 
after age 70). In a report from the Framingham Heart Study the risk of developing AF from age 80 to age 95 
was 23 percent for men and 22 percent for women.8 
Physiopathology. Irrespective of the underlying risk factors, changes in the anatomy and 
electrophysiology of the atrial myocardium are likely important. Thus, AF is usually associated with some 
underlying heart disease. Atrial enlargement, an elevation in atrial pressure, or infiltration or inflammation 
of the atria are often seen. Atrial premature beats appear to be most important as a trigger in patients with 
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paroxysmal AF who have normal or near-normal hearts. Hypertensive heart disease and coronary heart 
disease are the most common underlying chronic disorders in patients with AF. Hypertension increased the 
risk of developing AF 1.42-fold: although this is a relatively small increase in risk, the high frequency of 
hypertension in the general population results in hypertensive heart disease being the most common 
underlying disorder in patients with AF. 7.  
Almost any valvular lesion that leads to significant stenosis or regurgitation is associated with the 
development of AF but rheumatic mitral valve disease, although now uncommon in developed countries, is 
associated with the highest incidence of AF.9  
Other factors that may enhance and cause AF in patients are: heart failure, usually because 
associated with mitral regurgitation and increased left atrial pressures,  hypertrophic cardiomyopathy, 
congenital heart disease (both with and without surgical correction) and venous thromboembolic disease 
(the mechanism is unclear but has been speculated to be related to the increase in pulmonary vascular 
resistance and cardiac afterload, which may lead to right atrial strain). AF also occurs in chronic obstructive 
pulmonary disease (especially obstructive sleep apnea), peripartum cardiomyopathy, lupus myocarditis, and 
both idiopathic and uremic pericarditis. 
Diabetes, metabolic syndrome, and chronic kidney disease are medical conditions associated with 
the development of AF, probably because these comorbidities cause increased left ventricular mass and 
increased arterial stiffness. Systemic inflammation may also play a role. 
Potentially reversible triggers for AF include: surgery (especially cardiac and thoracic surgery), 
hyperthyroidism (probably for an increase in beta adrenergic tone), acute alcohol intake10, 
hypomagnesemia.11 
Clinical evaluation. AF can have adverse consequences related to a reduction in cardiac output. 
Typical symptoms include palpitations, tachycardia, fatigue, weakness, dizziness, light-headedness, reduced 
exercise capacity, increased urination, or mild dyspnoea. More severe symptoms include dyspnoea at rest, 
angina, pre-syncope, or infrequently, syncope. In addition, some patients present with an embolic event or 
the insidious onset of heart failure (as manifested by pulmonary oedema, peripheral oedema, weight gain, 
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and ascites). The disease facilitates the development of left appendage thrombosis and therefore exposes 
patients to higher risk of systemic thrombo-embolism (TE). Indeed, AF patients showed higher mortality and 
morbidity rates compared to the control population, mainly driven by the increase in ischemic stroke 
incidence.12  
 
1.2 Ischemic risk stratification in atrial fibrillation 
Every patient with AF should be evaluated for the need of oral anticoagulant therapy (OAT) to 
prevent systemic embolization even for the first AF episode; however, AF patients have different risks of 
developing stroke. The presence of a mechanical valve or significant mitral valve rheumatic disease directly 
exposes the patient to a very high risk of TE and therefore in this class of individuals anticoagulation is always 
mandatory.13 In the absence of these features, the disease is called “non-valvular atrial fibrillation” (NVAF) 
and it will be the main topic of the present work.   
Currently, European guidelines recommend calculating TE risk in NVAF patients by using the 
CHA2DS2-VASc risk score.13 (figure 1.2) 
Figure 1.2 the CHA2DS2-VASc risk score 13 
 
CHA2DS2-VASc score have proven to directly correlate with the annual risk of ischemic stroke in 
untreated NVAF patients.14 In one contemporary study, the annual risk of ischemic stroke in untreated 
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patients was 0.2, 0.6, and 2.2 percent for those with CHA2DS2-VASc scores of 0, 1, and 2.15 (figure 1.3) Many 
antithrombotic (anticoagulant and antiplatelet) strategies have been evaluated in clinical trials. These trials 
and their meta-analyses have consistently demonstrated that among patients with NVAF at moderate to high 
TE risk (i.e. CHA2DS2-VASc ≥2), warfarin significantly reduces the incidence of clinical stroke (by about two-
thirds) at an acceptable risk of bleeding compared to placebo.16 OAT to prevent TE is recommended for all 
male AF patients with a CHA2DS2-VASc score of 2 or more and in all female patients with a CHA2DS2-VASc 
score of 2 or more. Only patients with a CHA2DS2-VASc score of 0 (i.e. with no risk factors for stroke) are truly 
considered at low risk of ischemic events and should not take OAT because the risk of bleeding outweigh the 
risk of stroke. Also, female patients with no other risk factors (CHA2DS2-VASc score of 1) should not be 
anticoagulated.13   
The recommended treatment for patients with a CHA2DS2-VASc score of 1 (or 2 if female) is still 
debated, because in this cohort of patients the net clinical benefit of anticoagulation is unclear and risk 
factors does not carry the same risk of ischemic stroke thus complicating a standardized recommendation.13 
Presently, guidelines suggest to consider OAT, evaluating individual characteristics and patient preferences. 
Figure 1.3 Annual stroke event rate in NVAF untreated patients stratified by CHA2DS2-VASc score17 
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1.3 Oral anticoagulant therapy: vitamin K antagonist 
Many antithrombotic drugs, such as anticoagulants and antiplatelets, have been tested in the last 20 
years: adjusted-dose of warfarin (achieving an international normalized ratio –INR between 2.0 and 3.0) has 
proven to be the most effective therapy against ischemic complications and death. These results have been 
obtained in several historical trials18-25 and confirmed by further observational registries.26,27 
 Mechanism of action. Warfarin and other vitamin K antagonists (VKA, e.g. acenocoumarol, 
phenprocoumon, fluindione) block the function of the vitamin K epoxide reductase complex in the liver, 
leading to depletion of the reduced form of vitamin K that serves as a cofactor for gamma carboxylation of 
vitamin K-dependent coagulation factors.28. Without gamma carboxylation, the vitamin K-dependent factors, 
including factors II (prothrombin), VII, IX, and X, are immunologically detectable, but they cannot function 
because they cannot adequately bind calcium and phospholipid membranes needed for their haemostatic 
function. 
Thus, the ultimate anticoagulant effect of VKAs is delayed until the previously synthesized, functional 
clotting factors are cleared from the circulation. Depletion of both factor X and factor II (prothrombin) is 
important for clinical efficacy, and factor II has the longest half-life of the vitamin K-dependent factors 
(approximately three days) and therefore the desired anticoagulant effect of a VKA does not occur for at least 
three days after drug initiation despite prolongation of the prothrombin time (PT) at earlier time points. The 
initial prolongation of the PT is due primarily to depletion of factor VII, which has a short half-life (four to six 
hours).29 
VKAs also inhibit vitamin K-dependent gamma carboxylation of the anticoagulant factors protein S 
and protein C, which inhibit activated factors VIII and V. Thus, warfarin has a transient procoagulant effect 
during the first day or two of use. This is rarely of clinical significance, with the possible exception of patients 
who receive "loading doses" of warfarin (especially those with inherited protein C deficiency) who may 
(rarely) develop warfarin-induced skin necrosis. 
Metabolism. VKAs are absorbed via the gastrointestinal tract, circulate bound to albumin, and 
accumulate in the liver. Warfarin reaches maximal blood concentrations approximately 90 minutes after oral 
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administration; only the non-protein-bound fraction is biologically active. Commercially available warfarin 
and acenocoumarol are racemic mixtures of S and R enantiomers. S-warfarin is more potent than R-warfarin 
and is metabolized primarily by the hepatic cytochrome P-450 2C9 isoform (CYP2C9). Therefore, the overall 
anticoagulant effect of warfarin is influenced by CYP2C9 genotype and CYP2C9 drug interactions (eg, 
medications, over-the-counter herbal remedies). VKA drugs significantly differ in their half-lives: for warfarin 
is  36 to 42 hours, for acenocoumarol 8 to 11 hours and for phenprocoumon three to five days or longer.  VKA 
agents demonstrated different anticoagulant powers.30 
INR control. At therapeutic levels of anticoagulation, VKA prolong the PT, which reflects the extrinsic 
pathway of coagulation in vitro. Most laboratories and portable devices report the results of the PT along 
with an INR, a parameter that standardizes the PT value to an international reference thromboplastin 
standard.  For patients who are stably anticoagulated with a VKA, the percentage of time in the therapeutic 
range (TTR) is often used as a measure of the quality of anticoagulation control. TTR can be calculated using 
a variety of methods but the most used is the linear interpolation methods proposed by Rosendaal.31  High 
quality anticoagulation (i.e. when INR controls are in therapeutic range for more than 70% of the time, as 
recommended by European guidelines32) is associated with lower risk of both ischemic and bleeding events. 
Patients with higher TTR (time in therapeutic range) have a significantly reduced risk of all anticoagulation-
associated adverse events.33 Moreover, in a recent post-hoc analysis of RE-LY trial (comparing dabigatran 
versus warfarin), high TTR (>72.4 %) correlated to a reduced risk of both TE and MB.34 Nevertheless it is 
important to highlight that bleeding may occur also in patients with optimal INR control. 
 
Therefore, VKA therapy requires constant INR monitoring through blood samples and the dosing 
must be adjusted in order to maintain a certain target INR (usually 2.5). Significant overcoagulation or under-
coagulation expose the patient to the risk of bleeding or thrombosis, respectively.  
In order to minimize bleeding risk, VKA therapy should be carefully monitored, as a large number of 
variables are associated with fluctuation of anticoagulant activity. Factors that most commonly influence 
warfarin dose requirement are: nutritional status (including vitamin K intake); medication adherence; genetic 
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variation; drug interactions; smoking and alcohol use; renal, hepatic, and cardiac function; hypermetabolic 
states.Significant chronic disease (e.g., severe heart failure, liver disease, alcohol abuse, cancer, diabetes) is 
associated with reduced warfarin metabolism and more difficult INR control.  
1.4 Bleeding in anticoagulated patients  
When prescribing anticoagulation, the clinician should always balance the risk of stroke against the 
risk of bleeding in that particular patient. While ischemic risk is rather well predicted by current risk scores, 
estimation of bleeding risk has been and currently is a challenge. There are numerous factor that may impact 
on bleeding risk. The most important are listed: 
- Hypertension (especially when systolic blood pressure is >160 mmHg) 
- Labile INR or time in therapeutic range <60% in patients on VKA 
- Medication predisposing to bleeding, such as antiplatelet drugs and non-steroidal anti-inflammatoy 
drugs 
- Excess alcohol intake 
- Anaemia 
- Impaired renal function, Dialysis-dependent kidney disease or renal transplant 
Impaired liver function or Cirrhotic liver disease 
- Reduced platelet count or function 
- Older age 
- History of major bleeding (MB) 
- Previous stroke  
- Malignancy 
- Genetic factors 
A large number of studies have tried to develop scores for bleeding risk assessment in warfarin-
treated individuals, but presently only three have been derived and validated in AF populations: the 
HEMORR2HAGES35, the ATRIA36 and the HAS-BLED37 scores (Figure 1.4). However, attempts to validate such 
scores in external cohorts showed conflicting results:15 in several studies these scores showed only modest 
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power to predict bleeding events38,39 and in a prospective validation trial none of them showed a better 
performance compared to the physician’s subjective assessment.40 Moreover, considering only fatal bleeding 
or ICH, the HEMORR2HAGES and the ATRIA scores failed to show a significant predictive performance.38  
Figure 1.4 Comparison of different bleeding risk scores used in clinical practice. Adapted from41 
 
Therefore, none of the proposed score is able to reliably predict the actual bleeding risk in the single 
patient, although they have the unquestionable quality to highlight risk factors that can be actively managed 
(particularly HAS-BLED).  
Hemorrhagic stroke caused by spontaneous intracranial hemorrhage (ICH) is the most fearful OAT 
side effect, being related to very high rates of mortality and disability.42 Multiple observational studies and 
randomized trials report the risk of ICH attributable to anticoagulant therapy with warfarin to be in the range 
of 0.2 to 0.4 percent per year.  
It should be noted, however, that the prevention of ischemic stroke with OAT is so efficacious that 
in most AF patients the advantages of anticoagulation outweighs the risk of bleeding. It has been 
demonstrated that the net clinical benefit in NVAF patients (i.e. the estimated reduction in rate of TE minus 
1.5 times the estimated increase in rate of ICH attributable to OAT), is always in favour of OAT therapy except 
for those patients at very low ischemic risk.43  
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Based on these results, guidelines suggest calculating both ischemic and bleeding risk before 
undertaking OAT, but whereas the former is determinant in anticoagulation decisions, the latter should not 
be used to exclude patients from OAT.32  
 
1.5 The advent of non-vitamin K oral anticoagulation: new horizons  
In the last few years, a complete new class of oral anticoagulants, known as NOAC, have been tested 
in large RCT for stroke prevention in NVAF. The advent of NOAC has finally widened the therapeutic options 
for TE prevention in patients with NVAF, once relegated only to the VKA drugs. 
NOAC are profoundly different from VKA as they act as direct inhibitors of either thrombin (i.e. 
dabigatran), or FXa (i.e. rivaroxaban, apixaban and edoxaban), while VKA acts by inhibiting the production of 
all vitamin-K dependent coagulation factors. Key pharmacological characteristic are displayed in figure 1.5. 
Figure 1.5 Pharmacological characteristic of oral anticoagulants drugs. Adapted from:41 
 
Important additional advantages of NOAC agents include convenience (no requirement for routine 
testing of the INR), a high relative but small absolute reduction in the risk of ICH, lack of susceptibility to 
dietary interactions, and markedly reduced susceptibility to drug interactions.44 Disadvantages include lack 
of efficacy and safety data in patients with chronic severe kidney disease, lack of easily available monitoring 
of blood levels and compliance, higher cost, and the potential that unanticipated side effects will 
subsequently become evident.  
All four NOAC evaluated in large phase III trial (overall more than 40.000 patients treated) have 
proven to be at least as effective as warfarin in the prevention of stroke (ischemic and hemorrhagic) and 
systemic embolism. This benefit was mainly driven by substantial protection against all type of ICH (including 
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hemorrhagic stroke), which were reduced by half. The most recent metanalysis45 comparing all four NOAC 
against standard VKA therapy in patients with NVAF found: 
- a significant reduction of stroke/systemic embolism (relative risk 0.81, 95% confidence interval 0.73-
0.91, p<0.0001); 
- a non-significant 14% reduction in major bleeding (relative risk 0.86, 95% CI 0.73-1.00; p=0.06). 
- as secondary outcomes (figure 1.6), a significant and marked relative reduction in haemorrhagic 
stroke (relative risk 0.49, 95% CI 0.38-0.64, p<0.0001), a mild, although significant, gastro-intestinal 
bleeding increase (relative risk 1.25, 95% CI 1.01-1.55, p<0.0001) and a significant reduction in all-
cause mortality (relative risk 0.90, 95% CI 0.85-0.95)  
 
Figure 1.6 Meta-analysis of large trials comparing NOAC versus VKA. Efficacy and safety endpoints 45 
 
  
It is not possible to make a head-to-head comparison among these drugs in the absence of ad-hoc 
studies but the clear and strong superiority of NOAC in respect to warfarin for the prevention of hemorrhagic 
stroke was consistent in all the trials and with all the dosage tested. Interestingly, as shown in a post-hoc 
analysis of the RE-LY trial, the rates of ICH in the warfarin group were not associated with the time in 
therapeutic range (TTR) and were consistently higher in comparison with dabigatran.34  
Low-dose regimens (i.e. dabigatran 110 mg x246 and Edoxaban 30mg47) showed the largest reduction 
in hemorrhagic stroke compared with warfarin even if associated with an increase in ischemic stroke 
(significant for edoxaban, non-significant for dabigatran). 
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 Dabigatran 150 mg bid46 and Apixaban 5 mg bid48 showed superiority versus warfarin for the 
composite outcome of stroke and systemic embolism, while rivaroxaban 20mg qd49 and edoxaban 60mg qd47 
showed non-inferiority. Different designs of the studies may account for such differences.  
A recent analysis on a “real world” AF population treated with all different OAT therapy commercially 
available, found that for patients with CHADS2 score ≥1 and CHA2DS2-VASc score ≥2 the three new drugs 
performed better than warfarin for net clinical benefit, regardless of risk of bleeding (assessed by HAS-BLED 
score). At CHA2DS2-VASc score =1 only apixaban and both doses of dabigatran appeared to have a positive 
net clinical benefit.50  
The absence of a direct reversal agent for all NOAC is a matter of concern among clinicians. At 
present, only dabigatran has developed and commercialized a direct and specific antidote, idarucizumab.51 
The outcome of patients enrolled in phase III RCTs suffering from MB and its severity seems to be better in 
the group treated with NOAC than in the group treated with warfarin.5,52,53  
Another concern is renal function, as all NOAC are partially excreted by the kidney. NOAC 
demonstrated a good efficacy and safety profile in moderate to severe renal impairment (Creatinine 
clearance 30-50 ml/min): in particular apixaban showed a reduction in the risk of bleeding compared with 
warfarin, while dabigatran and rivaroxaban reported no significant differences.54 In patients with severe 
kidney impairment (CrCl <30 mL/min), all NOAC are contraindicated because they have not been tested in 
clinical trials. Rivaroxaban, apixaban and edoxaban trials used a reduced dose drug in presence of impaired 
renal function (rivaroxaban 15 mg daily49 and half edoxaban dose – i.e. 30 mg or 15 mg depending on the 
two arms of the study47 if estimated clearance was 30-50 mL/min, apixaban 2.5mg bid if reduced clearance 
was accompanied by age ≥80 years old or weight ≤60 Kg48). Even if it was not tested in the trial, reduced dose 
dabigatran (110 mg x 2, not available in the United States) should be used when estimated clearance is 30-
50 mL/min, as a precaution, because it is the NOAC with greatest renal metabolism (see Figure 1.5).46  
Therefore, NOAC appear to be safer than warfarin in the prevention of ICH in patients affected by 
NVAF. However, it is important to note that NOAC are at present contraindicated in all the group of patients 
in which they have not been tested, such as severe renal and/or liver impairment, and during pregnancy. 
29 
 
Dabigatran has been tested on patients with mechanical heart valves but the study was terminated 
prematurely because of an increased rate of TE and ICH with NOAC.55 Therefore NOAC are not presently 
indicated in valvular AF. 
Single or double daily administration, patients’ co-morbidities, trial-proven efficacy in different 
subsets of patients and reported rate of extra-cranial bleeding will guide the clinician’s decision for the choice 
of the most suitable NOAC in every single patient.   
 
1.6 Alternatives to oral anticoagulation 
Aspirin. Aspirin has been evaluated as an alternative to warfarin for the prevention of TE in NVAF. 
However, in the last decade, many studies and meta-analyses56 showed that anticoagulants are significantly 
more effective than aspirin,57 aspirin + clopidogrel58 and aspirin + fixed low dose of warfarin21,59 at stroke 
prevention. It has been advocated that antiplatelet therapy may be safer than OAT in regards to MB and ICH; 
however the “Birmingham Atrial Fibrillation Treatment of the Aged” (BAFTA) study clearly showed that in 
elderly patient with NVAF, the incidence of  MB and ICH is the same with aspirin and warfarin.57  
Left atrial appendage closure. Left atrial appendage (LAA) closure is a new way to reduce TE in NVAF 
patients without the use of OAT.  During AF, the LAA becomes a major site of blood stasis, indeed it seems 
that it is the site for thrombogenesis in more than 90% cases evaluated with trans-esophageal imaging.60 
Therefore, surgical and transcatheter techniques have been explored to reduce the risk of stroke by excluding 
or occluding the LAA: while surgical procedures lacks of large RCT and results are still controversial, a RCT 
have shown that percutaneous LAA closure (with Watchman device) is non-inferior to standard anti-
coagulant treatment for the prevention of TE in selected NVAF patients.61 However many caveats remains 
such as the high periprocedural complication, mainly driven by inexperienced operators, the small but 
present risk of haemopericardium, the need of dual antiplatelet therapy for a range of time that expose the 
patient at high bleeding risk and the risk of incomplete closure/dislodgment of the device. At present LAA 
closure is not an alternative to OAT for stroke prevention in NVAF. Current ESC guidelines recommend that 
percutaneous LAA closure “may be considered in patients with a high stroke risk and contraindications for 
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long-term oral anticoagulation” with a level of evidence “B.”12 In particular this alternative should be 
evaluated in patients with recurrence of ischemic events or new appearance of hemorrhagic stroke during 
well-conducted OAT or in patients refractory or incapable to assume OAT. Preliminary studies seem to 
confirm the efficacy and safety of the procedure in patients with previous ICH, 62 however, until more data 
will be available, this procedure should be limited to restricted groups of patients in which OAT therapy is 
associated to very high risk of complications or is contraindicated (figure 3.2).  
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2. VITAMIN K ORAL ANTICOAGULANTS IN THE ELDERLY 
Vitamin K oral anticoagulants (VKA) are reportedly still being underused in the elderly. 63,64 There is 
ongoing debate and contradictory evidence concerning whether older age exposes patients to a higher 
bleeding risk even with high-quality anticoagulation65-67. The incidence of bleeding is influenced by the quality 
of anticoagulant management but data on the elderly population are inconsistent. Elderly frequently 
discontinue treatment, but reasons and consequences are poorly investigated. In this special subset of 
patients, moreover, little is known whether to restart or not anticoagulation after a MB event, as the net 
clinical benefit of anticoagulation in frail and/or elderly patients may be reduced or absent.  
To contribute to the debate, we design a subset of studies using data from patients referring to our local 
anticoagulation clinic, the Padua Thrombosis Centre.  
 
2.1 Padua Thrombosis Centre  
The Padua Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to 
the diagnosis and treatment of hypercoagulable conditions. The Padua Thrombosis Centre forms part of the 
Department of Cardiac, Thoracic and Vascular Sciences, an academic clinical unit of the Azienda Ospedaliera 
di Padova. It is affiliated to the Italian Federation of Thrombosis Centres (FCSA): FCSA centres are required to 
give patients who start the treatment adequate education on the purpose of the treatment, the risk of 
complications, INR values, and treatment management. They follow up patients by periodic INR 
measurements; establish the date for subsequent visits; prescribe the daily VKA dosages; and monitor and 
record changes in patients’ habits, diet, comedications, intercurrent illnesses, bleeding, and thrombotic 
complications through patient interviews. Patients followed in FCSA-affiliated Thrombosis Centres 
demonstrated a better quality of anticoagulation measured as Time in Therapeutic Range (TTR): over a 5-
year observation time, it has been observed a constant increase in TTR, from 64.8% (range 49.2–75.5%) in 
2009 up to 67.9% (range 52.2–86.6%) in 2013; the percentage of Centres with a TTR above 60% was 83.9 in 
2009 and 93.6 in 2013.68 Presently, Padua Thrombosis centre present a centre TTR of around 70%. 
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2.2 The VENPAF trial 
Initially, our aim was to determine the incidence of TE and MB in our elderly reference population: thus, 
we performed a single-centre, inception cohort retrospective follow-up study called VENPAF, very elderly 
naïve patients with NVAF. 
Methods. We screened 4563 patients referring to the Padua Thrombosis Centre from January 2007 
to January 2012. All patients ≥80 years old with NVAF (INR range 2-3) were considered for inclusion in the 
study. They were excluded if they were already on VKA therapy at the baseline, or had been in the previous 
2 years, or if they suspended VKA within a month of starting the treatment, unless a bleeding event occurred 
earlier.  
Of the 2757 patients with NVAF being followed up at our centre during the 5-year period considered, 
891 were at least 80 years old; 93 of these patients did not meet our inclusion criteria (40 were not 
anticoagulant-naïve, 52 had been followed up for less than 1 month, and data were lacking for 1), so the final 
VENPAF cohort consisted of 798 patients. Patients’ demographics and clinical baseline information were 
collected for analysis from the electronic records held at the Padua University Hospital and the 
Anticoagulation Clinic, or by means of telephone calls to family physicians. Comorbidities like hypertension, 
diabetes mellitus, and heart disease were defined according to the corresponding guidelines.69-72 The TE risk 
profile was calculated using the CHADS2 score.73 The quality of anticoagulation was calculated as the time in 
the therapeutic range (TTR) from starting the treatment to the end of the follow-up, using the linear 
interpolation method devised by Rosendaal et al. 31 The resulting TTR included all INR data available during 
the observation period, including when the therapy was started, and any temporary suspensions for invasive 
procedures requiring heparin bridging. 
TE and MB were detected through the Padua University Hospital electronic records and direct contact 
with the family physician. Ischemic stroke and transient ischemic attack were defined as a sudden neurologic 
deficit in the absence of cerebral hemorrhage on neuroimaging, with evidence of a focal ischemic lesion on 
subsequent examinations.74 MB was defined according to the ISTH criteria as fatal bleeding and/or 
symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-
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articular, pericardial, or intramuscular with compartment syndrome) and/or bleeding causing a fall in the 
haemoglobin level of 20 g/L or more, or leading to transfusion of two or more units of whole blood or red 
blood cells.75 
Patients’ clinical characteristics. Baseline patient demographics are shown in Table 2.1, for the whole 
sample and by age group. The VENPAF sample included 485 females (60.8%) and the mean age was 84.4 
(±3.3) years. Among the oldest patients, the prevalence of female gender and the heart failure rate were 
significantly higher (p=0.007 and p=0.002, respectively) and so was the CHADS2 score (2.72 vs. 2.51, p=0.003). 
Table 2.1 Baseline characteristics of the cohort 
 
Major Bleeding (MB). The 798 patients considered were followed up for a median 2.2 years (IQR 1.2-
3.5 years) for a total observation time of 1,912 years. Among those, 15% (120) died, 18.5% (148) suspended 
VKA before the end of the follow up and 6.6% (53) were monitored elsewhere (e.g. by their general 
practitioners or at other anticoagulation centres). There were 65 MB events (3.4 per 100 patient-years) 
during the follow-up (Table 2). Sixteen (24.6%) were fatal, 38 (58.5%) needed hospitalization or blood 
transfusions, 6 (9.2%) needed surgery or invasive intervention to stop the bleeding, and 5 (7.7%) were treated 
in an outpatient setting. It is noteworthy that 29 MB episodes were intracranial (1.5 per 100 patien-tyears), 
and 18 (0.9 per 100 patient-years) involved the gastrointestinal tract. Most of the MB events recorded were 
spontaneous (58.5%), while 29.2% were post-traumatic, and this information was not available for 12.3%. 
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The mean HAS-BLED score for the 65 patients who bled was 2.86 (±1.0). Patients experiencing MB episodes 
were a mean 84.8 (±2.7) years old. As shown in Table 2, patients over 85 years old had significantly more 
events than the 80-84 year-olds (4.7 vs. 2.6 per 100 patient-years, p<0.01). The older patients also had a 
higher rate of gastrointestinal bleeding, and significantly more spontaneous bleeding episodes (3.0 vs. 1.3 
per 100 patient-years, p 0.008). The Kaplan-Meier survival curves very soon diverge significantly, as shown 
in Figure 1 (HR 1.8, 95%CI 1.1-3.0 p=0.014).  
Figure 2.1 Cumulative frequency (Kaplan–Meier curve) of major bleeding events during the follow-up by 
age group (80–84 vs. C85) 
 
Thromboembolic events (TE). There were 25 TE during the follow-up (1.3 per 100 patient-years) 
(Table 2), in patients with a mean age of 84.5 (±2.7) years; 24 of them were strokes (1.2 per 100 patient-
years), and 3 were fatal. To weigh the risks and benefits of administering anticoagulants in our observational 
cohort, we compared the rates of MB events actually observed with the TE rates that patients might have 
been expected to experience without taking oral anticoagulants (figure 2.2), given that oral anticoagulants 
are known to lower TE rate by 64 %, thus preventing approximately two in three of such events.16 
 
We therefore ascertained that MB in elderly patients anticoagulated with VKA is 3.4 % patient-year 
and this picture is higher than what reported in previous studies66,76-79, which described bleeding rates in the 
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range of 1.1–2.9 per 100 patient-years. However, the theoretical ischemic risk in this cohort seems to 
overcome the actual bleeding risk (figure 2.2) even in the most elderly patients.  
Figure 2.2 Observed major bleeding events vs. calculated thromboembolic events by age group 
 
 
2.3 Reasons and consequences of warfarin discontinuation 
Another issue concerning anticoagulant underuse in the elderly is persistency that is defined as the 
length of time between therapy initiation and its discontinuation.80 Discontinuation may be due either 
because patients never start taking the drug, or because they discontinue it after complications or side 
effects. Discontinuation rates for long-term VKA treatment in patients with NVAF are generally high 81,82 and 
tend to be higher in very old patients and among long-term-care residents.57,64,83 Outcomes after VKA 
discontinuation in randomized trials have been reported,84 but data for a ‘real-world’ population on reasons 
for discontinuation, subsequent therapeutic strategies and consequences are scarce. 
The aim of our study was to report the reasons for warfarin discontinuation, the prescribed treatment 
after discontinuation and the clinical outcomes in the VENPAF cohort.  
Methods. Warfarin discontinuation was defined as a period of at least 180 consecutive days in which 
there were no sequential INR measurements.85 These patients were screened, and the 
following data were collected: (i) the person who took the decision to stop treatment; (ii) the reason given 
for discontinuation; and (iii) the alternative treatment used after warfarin discontinuation. Patients who 
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discontinued warfarin were followed for at least 6 months, and censored in cases of warfarin resumption, 
TE, MB, or death. In this period, the occurrence of TE or MB after warfarin suspension was registered. 
TE and MB were defined as previously reported,86 and detected through the Padua University 
Hospital electronic records and direct contact with the family physician. To reduce biases resulting from the 
observational nature of the study, all data were collected and processed by the same team of investigators, 
who crosschecked the electronic databases. 
Results. One hundred and forty-eight patients (18.5%) discontinued warfarin after a median of 14 
months of therapy. CHADS2 and CHA2DS2-VASc scores were similar among patients who discontinued and 
patients who continued warfarin. Vascular disease was significantly more frequent in patients who 
discontinued oral anticoagulation. 
During warfarin therapy, the frequency of outcome events was significantly higher and the quality of 
treatment was significantly lower in patients who discontinued the treatment. Despite similar CHA2DS2-VASc 
scores, TE occurred in 3.14 per 100 patient-years versus 1.05 per 100 patient-years (P = 0.01). MB occurred 
in 10.8 per 100 patient-years versus 2.4 per 100 patient-years (P = 0.001), and the TTR was 58% versus 62% 
(P < 0.001). 
Multivariate Cox regression analysis (Table 2.2) identified the following as independent factors 
associated with therapy discontinuation: vascular disease (HR 2.5, 95% CI 1.5–3.9, P < 0.001), age ≥ 85 years 
(HR 1.4, 95% CI 1.1–1.9, P = 0.04), TTR < 60% (HR 1.8, 95% CI 1.3–2.5, P = 0.001), and bleeding events (HR 2.3, 
95% CI 1.4–3.6, P < 0.001). 
Reasons for warfarin discontinuation. As shown in Table 2.3, in most cases, the decision to 
discontinue was made by the specialist (80.4%) or by the general practitioner (12.8%), and in a few cases the 
decisionwas made by the patient (1.4%). The main reason for warfarin discontinuation was physician-
perceived low life-expectancy (i.e. < 12 months) or frailty (45.9%), followed by bleeding side effects (19.6%) 
and sinus rhythm restoration (16.9%). Other physicians’ concerns included logistic difficulties in therapy 
monitoring (4.1%), low patient compliance (3.4%), and polypharmacotherapy (0.7%). Treatment after 
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warfarin discontinuation was equally distributed among low molecular weight heparins (LMWH) (33.1%), 
antiplatelets (29.1%), and no antithrombotic therapy (27.7%). 
Table 2.2 Multivariable Cox analysis of clinical factors associated with warfarin discontinuation 
 
Analysing patients according to reasons for suspension, frail patients and those with low life-
expectancy were more frequently using anticoagulant therapy with LMWH after warfarin discontinuation 
than aspirin or no treatment (P = 0.006).  
Table 2.3 Analysis of patients who discontinued warfarin 
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Outcomes after discontinuation. The cohort of patients who discontinued warfarin was followed for 
a median of 25 months after discontinuation. Ninety-four of 148 patients (64%) died during follow-up, and 
death occurred especially in patients who experienced an ischemic or haemorrhagic event after 
discontinuation (21 deaths of 26 events, 81%). The cumulative incidence of at least one event among 
ischemic strokes, MB and deaths was especially high in frail patients, in those with low life-expectancy (most 
of whom were treated with LMWH) and in patients who discontinued warfarin because of bleeding 
complications.  
 
Discussion. In the present study, we found that very elderly warfarin naïve patients with NVAF had a 
high warfarin discontinuation rate (18.5% of the entire cohort, with an incidence of 7.6% patients per year). 
This figure is slightly lower than those reported in less recent studies, which vary from 20% to > 30%. 64,85,87-
89 At variance with these reports, a very recent registry on an anticoagulated population (the ORBIT-AF 
registry) showed a discontinuation rate, in VKA-naive patients, of 17% over 1 year of follow-up, a result that 
is close to our finding.82 Whether or not the use NOAC enhances treatment continuation versus warfarin is 
not known, as the two treatments are not comparable in observational studies.90,91 Even in randomized 
studies, in which treated patients are comparable,46,49 continuation of NOACs was lower than that of 
warfarin.  
The demographic and clinical characteristics at baseline were not different between patients who 
continued treatment and those who discontinued treatment. During anticoagulant treatment, TE and MB 
determined warfarin discontinuation. The quality of treatment measured according to the TTR was 
significantly different between the two groups. In this study, we did not observe an influence of CHA2DS2-
VASc score on the quality of treatment, as previously reported.92 A higher quality of anticoagulation 
correlates with better outcomes,93 and this supports the current practice of patients with lower TTRs being 
evaluated for alternative treatments to avoid complications (e.g. NOACs and LAA closure).41,94 
Multivariate analysis of clinical factors showed that older age and bleeding events are closely related 
to warfarin discontinuation. Although the TTR is strongly associated with warfarin discontinuation, it was 
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probably not taken into account by the physician who discontinued the treatment, and it was not reported 
as a reason for discontinuation. Knowing a priori the quality of treatment of patients starting warfarin, as 
demonstrated by the SAME-TT2R2 score, would be very useful for selecting the correct treatment strategy.95 
Vascular disease was the factor most strongly associated with warfarin discontinuation, possibly suggesting 
that physicians were concerned about the risk of using multiple antithrombotic treatments in these high 
bleeding risk patients. MB rate increases with age,65 and the occurrence of haemorrhage automatically puts 
the  patient at high risk of re-bleeding with warfarin.96 Therefore, bleeding events are naturally associated 
with an increase in the bleeding risk perceived by the clinician, and have been confirmed in many studies64,97 
as one of the main reasons for discontinuation. Regarding age, some studies64 are in line with our results, 
arguing that older patients are more likely to suffer from therapy complication or side effects, inducing 
themselves or clinicians to stop the medication. Other studies82 have found an association of discontinuation 
with younger age, but this is probably related to low compliance. The decision regarding warfarin 
discontinuation and subsequent prophylaxis was usually taken by a hospital specialist, confirming previous 
reports.64 Very elderly patients are often hospitalized for an acute illness, inducing hospital clinicians to 
decide whether to prolong anticoagulation. In our cohort, perceived frailty and low life-expectancy and 
hemorrhagic complications account for most of the reasons given by the clinicians for discontinuation. The 
decision regarding discontinuation did not always follow guideline recommendations, as almost 17% of 
patients discontinued warfarin treatment because of claimed sinus rhythm restoration.98. Large variability in 
treatment after discontinuation was revealed: an alternative anticoagulant was used in one-third of cases 
(long-term subcutaneous LMWHs), in contrast to current guidelines.13 LMWHs were the preferred 
medications in frail patients and those with low life-expectancy. In contrast, the erroneous perception of low 
thromboembolic risk in sinus rhythm patients explains the discontinuation of any anticoagulant therapy. 
As far as the authors are aware, our study is the first to report the outcomes of very elderly patients 
with long-term indications for warfarin who discontinued treatment. Patients selected for discontinuation 
showed a very high mortality rate, driven by frailty and previous bleeding complications. Ischemic and 
haemorrhagic events frequently led to clinical deterioration, and eventually to death. Patients who 
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discontinued treatment because of bleeding or frailty had a high rate of ischemic events, bleeding events, 
and death, irrespective of anticoagulant prophylaxis. A recent study by Staerk et al. is in line with our results, 
showing that patients who restarted oral anticoagulation after gastrointestinal bleeding had lower mortality 
and TE rates than patients who did not resume treatment.99 Restoration of sinus rhythm probably identifies 
a healthy subgroup in elderly patients, and this may account for the absence of serious events during the first 
3 years of follow-up. However, discontinuation of anticoagulant treatment in this setting is quite debatable. 
These are, in fact, high-risk patients, and recurrent AF may be asymptomatic, owing to rate or rhythm control 
treatments. 
Limitations. The study was conducted on a single-centre cohort. Small numbers of events prevented 
us from using separate endpoints, and we therefore analysed data as a cumulative incidence of bleeding, 
ischemic events, and deaths. Our study is much smaller than other studies considering discontinuation in 
patients treated with VKA.85,87-89 However, despite the relatively small numbers of patients and events, data 
collection was performed with extreme precision: no patients were lost to follow-up, and information was 
obtained using different databases and telephone contacts with general practitioners. This enabled us to 
reliably identify all events occurring during follow-up. Moreover, the inception cohort nature of our study 
allowed us to avoid the biases inherent in survival populations and selection biases, because our cohort was 
included all patients fulfilling the inclusion criteria from among the total population attending our 
anticoagulation clinic. We were not able to assess the currently used bleeding risk scores from the data of 
our database. However, as shown in our previous study, the HAS-BLED score did not appear to predict MB 
events: patients experiencing such events had a mean score below the high-risk cut-off of 3.86 We observed 
a very high mortality rate (64%) in patients who discontinued warfarin, and this finding may be consistent 
with the high proportion of frail patients and their very advanced age. Mortality could have prevented more 
ischemic and/or hemorrhagic events from occurring, and the cause of death was often unknown, as most 
patients died outside the hospital. 
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2.4 To treat or not to treat after major bleeding? 
MB rate increases with age64,65 and the occurrence of haemorrhage automatically puts the patient at 
high risk of re-bleeding with warfarin.96 Therefore, bleeding events are naturally associated with an increase 
in the bleeding risk perceived by the clinician, and have been confirmed in many studies64,97 as one of the 
main reasons for discontinuation. The decision to restart or not OAT after MB is usually problematic. 41 Data 
referring to elderly patients are scarce and controlled trials in this setting are lacking.  
We therefore analysed the subgroup VENPAF patients who experienced a MB while on warfarin. TE 
and MB after the index event were examined in relation to the restarting OAT. 
Methods. This is a nested subgroup analysis of the VENPAF inception study. Patients who 
experienced a non-fatal MB during OAT were subsequently followed up and outcomes after the index event 
were recorded. Warfarin discontinuation was defined as previously reported.100  TE and MB were detected 
through the Padua University Hospital electronic records and direct contact with family physicians and 
defined according to specific guidelines.74,75 Fatal bleeding was defined as death occurring during 
hospitalisation for MB. All patients were followed from the time of the first MB until the occurrence of a 
second outcome event (either TE or MB), death or the end of follow-up period (36 months), whichever came 
first. 
Results. During a median follow-up duration of 2.2 years, there were 65 MB with an incidence rate 
of 3.4 %patients/year. 16 MB were fatal (case fatality rate 25 %). Patients who experienced MB during OAT 
did not significantly differ from the total cohort in terms of age, gender, TTR and comorbidities. Patients with 
a fatal bleeding showed a significantly lower TTR (57.6 ± 15.1 % vs 64.5 ± 10.4 %, p<0.05) and significantly 
higher rate of ICH (81.3 % vs 32.7 %, p<0.001). 
Of the surviving 49 patients, 25 restarted and 24 permanently discontinued OAT. Patients 
were similar in terms of demographic and clinical characteristics (Table 2.4). However, a trend toward 
suspending OAT after ICH was noted. 
Patients were followed up for a total of 89 years. Twelve events were recorded: 2 in patients who 
restarted and 10 in patients who suspended OAT. 
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Table 2.4 Comparison of clinical and demographic characteristics of patients who discontinue 
or restarted oral anticoagulation after a major bleeding event. 
 
The events in patients who restart OAT were 2 MB while in patients who suspended were 4 MB and 
6 TE (Table 2.4). As shown in Figure 2.3, a statistically significant increase of events is present in patients who 
suspended OAT (p<0.05). 
The present analysis confirms that bleeding is a fearful and frequent complication in elderly 
patients.101 Gastrointestinal bleeding and ICH are more common and severe in the elderly102,103 and in our 
study accounted for 72 % of all MB. ICH was the most severe complication, responsible for 81 % of fatal 
haemorrhages, in line with previous reports.42 
Overall, we found a case fatality rate of 25 % after MB which is extremely high. Together with ICH, 
low TTR value was independently associated with fatal events. TTR identifies patients at higher risk of 
complication during warfarin treatment,104 but its association with ICH is still debated.34,105  
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Patients who resumed or discontinued warfarin after a non-fatal MB did not show statistical 
difference regarding basal demographic and clinical characteristics. However, differences between groups 
(e. g. higher number of ICH in patients who did not resume warfarin) may be non-significant due to low 
number of cases. 
Figure 2.3 Cumulative rate of ischaemic and bleeding events after the index event in patients 
who experienced a major bleeding, according to warfarin restart. 
 
The main result from this study is that patients who restarted OAT had fewer events (either MB or 
TE) than patients who suspended OAT. This observation confirms other reports99,106,107 which evaluated OAT 
after gastrointestinal bleeding. Our study is the only one to focus on elderly. Principal study strength is the 
absence of selection bias with no lost to follow-up and no missed events. The study presents some 
limitations, too: the analysis is retrospective and conducted on a single centre cohort; numbers of events are 
small and prevented us from using separate endpoints. 
 
After these results, we concentrate our efforts to better determine the risk of haemorrhagic stroke 
in anticoagulated individuals.  
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3. THE RISK OF HAEMORRHAGIC STROKE IN ANTICOAGULATED PATIENTS 
3.1 Haemorrhagic stroke and intracranial haemorrhage 
Haemorrhagic stroke is the most fearful OAT side effect, being related to very high rates of mortality 
and disability.108 Haemorrhagic stroke is a clinical syndrome defined as a sudden neurological dysfunction 
attributable to a intracranial haemorrhage (ICH) not caused by trauma.109 ICH can be classified according to 
the affected intracranial compartment as intra-parenchymal, intra-ventricular, subarachnoid, subdural, and 
epidural (figure 3.1). Subdural and epidural haemorrhages are most commonly related to head injury 
whereas subarachnoid haemorrhages are generally caused by the rupture of cerebral aneurysms. The most 
frequent type of ICH causing haemorrhagic stroke during OAT is intracerebral haemorrhage, which comprises 
intra-parenchymal and intra-ventricular bleeding occurring in the absence of trauma.  
Figure 3.1. Sites of Intracranial Haemorrhage (ICH)  
 
With an overall incidence of around 25 per 100 000 person-years,108,110 ICH is the second most 
common cause of stroke and it frequently bears a poor prognosis with very high case fatality rate, leading to 
permanent disability in almost 50% of the cases. In OAT patients, mortality raises to 67%, accounting for 
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about 90% of all bleeding related deaths.42,108 Non-traumatic ICH is mainly associated with uncontrolled 
hypertension, although in recent decades the proportion of hypertensive haemorrhages has greatly reduced 
thanks to the increased awareness of the importance of blood pressure control.110 On the contrary, ICH is 
much more frequent in the elderly, with a 9-fold increase in people aged ≥ 85y. vs. 45-54y.108 This result is 
probably driven by high prevalence of hypertension and amyloid angiopathy (a disease associated to arterial 
degeneration and micro-bleeds seen on cerebral magnetic resonance imaging)111 and by the increased use 
in this population of antithrombotic therapy. 
The use of antithrombotic drugs (i.e. anticoagulants and antiplatelets drugs) increases the incidence 
of ICH of approximately 10-15 times, making the bleeding more severe and difficult to treat.112 ICH and 
haemorrhagic stroke rates in patients treated with warfarin vary substantially among different studies: from 
0.1%/year in clinical randomised trials113 (Table 1) to 1.2%/year in “real-world” observational studies.64 These 
important differences are likely to be explained by the different study design and disease definition (in 
particular MB, ICH and haemorrhagic stroke definitions may vary across the studies), by selection bias or 
intensity and quality of monitoring in different centres. However, despite the variability of these reports, it 
should be acknowledged that in the last decades the incidence of anti-thrombotic associated ICH has 
increased and the outcome worsened.114 At present, it has been estimated that roughly 15% of all ICH are 
associated with the use of warfarin110,114 and, given the increasing number of NVAF patients treated with OAT 
and the predisposition of elderly to ICH, this number is likely to increase. 
 
3.2 Risk factors associated with haemorrhagic stroke 
A wide range of factors may increase the general risk of bleeding in patients treated with OAT.96,115-
117 Risk factors highly associated with cerebral bleeding are age, ethnicity and hypertension. Table 3.1 
summarize most supposed associations.    
Aging. Elderly are particularly prone to ICH, which are more frequent among people aged ≥75 years 
and are often fatal.42,112 High bleeding rates were found especially in the first year of treatment with 
warfarin.64 Confounding factors may account for these results, as elderly patients usually present high 
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incidence of other risk factors for ICH (i.e. hypertension, amyloid angiopathy, co-medication, comorbidities). 
Nevertheless, current guidelines recommend oral anticoagulation therapy in the elderly, based on a positive 
net clinical benefit favouring VKAs over no therapy.118 However, observational registries have shown higher 
incidence of MB in the “real world setting” compared with RCT.119 
Table 3.1 Risk factors associated with haemorrhagic stroke and intracranial bleeding41 
Life-style factors. Uncontrolled hypertension (i.e. systolic blood pressure >160 mmHg) is the most 
import risk factors for all stroke types, particularly for ICH116 and the concomitant treatment with OAT further 
increase the risk of bleeding. Tobacco seems to be associated with ICH (even if association is stronger with 
ischemic stroke) and a dose-response association for number of cigarettes smoked per day has been found.116 
Heavy alcohol intake is associated with the occurrence of ICH at a young age probably because of small-vessel 
disease early development and because of moderate haemostatic disorder through the associated liver 
impairment.120 Increased total and non-HDL cholesterol levels seem to be associated with a reduced risk for 
haemorrhagic stroke.116 However the association is poorly understood.  
Past medical history. A recent or remote history of stroke, either ischemic or haemorrhagic, and 
history of bleeding (any site) are strong risk factor for ICH 121-123  Severe and moderate liver impairment 
(defined as a Child Pugh class of B or C) is associated either with bleeding disorders (probably related to 
reduced production of coagulation factors, thrombocytopenia and altered platelet function) and to 
thrombosis, due to a reduced production of natural anticoagulant factors such as antithrombin, protein S 
and protein C and net effect in the single patient is not predictable.124 Renal impairment is a well-known risk 
factor both for bleeding and for thrombosis.125 Severe CKD (defined as a creatinine clearance <30 ml/min) 
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has been associated to increased risk of ICH in patients treated with warfarin, partly due to the suboptimal 
anticoagulation control of these subjects.126 However calculated net clinical benefit results positive in favour 
for OAT for all categories of renal function.127 
Co-medications. Concomitant use of anti-platelets with OAT increases the risk of bleeding. It has 
been reported that patients treated with VKA and aspirin have a 1.8 fold increase of bleeding risk compared 
to VKA alone and this risk is even higher for the combination of VKA and clopidogrel (HR 3.1), being the 
highest in patient with “triple” anti-thrombotic therapy (VKA, clopidogrel and aspirin, HR 3.8).128  RCT post-
hoc analyses and data on outcome in the setting of acute coronary syndrome, demonstrated that NOAC, as 
VKA, are associated with higher bleeding risk when combined with either single or dual antiplatelet 
therapy.129-131 Steroids and non-steroidal anti-inflammatory drugs (NSAD) may increase the risk of bleeding. 
While their use has been associated with gastrointestinal bleedings, they seem not to increase the risk of 
ICH.132 A retrospective Chinese cross-over study, however, suggest that the use of parenteral ketorolac may 
expose the patients to higher risk of ischemic and haemorrhagic stroke133, but further confirmations are still 
lacking. 
Brain imaging alteration. There are growing data that some brain features expose the patient to 
higher risk of bleeding, such as leukoaraiosis (i.e. white matter abnormality seen on computed tomographic 
scan), vascular malformations, tumours or amyloid angiopathy.134 Brain imaging is now able to detect 
microbleeds, a sign of severe microangiopathy.135 Microbleeds and amyloid deposition are associated with a 
high ICH rate that is further increased by antithrombotic therapy, even if the INR is well controlled.136,137 It 
should be noted, however, that Alzheimer’s disease itself is not a strong risk factor for cerebral haemorrhage 
and should not be viewed as an absolute contraindication for antithrombotic therapy.  
Other risk factors for ICH. Risk of falls is perceived as one of the main risk factors for withholding 
anticoagulation, and may lead to an increased risk of ICH. However, not all experts agree: some researchers 
have calculated that a person on warfarin must fall almost daily to outweigh the benefit of anticoagulation,138 
while others found a substantial increase of  ICH, especially traumatic, in patients who are prone to fall.139 
Ethnicity has been advocated as one important risk factor for ICH. Rates of cerebral bleeding vary by different 
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race groups and it is particularly high in Black, Asians115 and Mexican-Americans.140 Genetic disorders may 
alter VKA metabolism thus exposing warfarin-treated patient to higher risk of bleeding. Current research 
mainly focus on cytochrome P450 2C9 polymorphisms and vitamin K epoxide reductase complex subunit 1 
gene (VKORC1) that alter sensitivity to VKA thus delaying the stabilization of VKA treatment.122 Apoliporotein 
alleles (i.e. Apo E4 and E2) are associated to an increased risk of cerebral bleeding, probably because their 
correlation with Alzheimer disease and parenchymal amyloid plaques.141 
 
3.3 A case control study at the Padua Thrombosis Centre 
 To evaluate whether there are factors associated to ICH during OAT, we developed a case-control 
study using data retrieved from the electronical records of the Padua Thrombosis Centre. We then evaluate 
the predictive role of haemorrhagic bleeding scores in our population for the outcome ICH.  
Methods. Patients eligible for the present study were retrieved retrospectively from the electronic 
medical records of the Padua Thrombosis Centre: PARMA software assists the clinicians in choosing the best 
dosage of VKA to maintain INR at target range. The software allows also to collect patient-related data and 
to store a clinical datasheet where all therapy-related complications, interfering drugs or relevant medical 
history are stored. Patient included in the present analysis were all ≥18 year-old patients who were on VKA 
because affected by NVAF. We selected the patients who, between January 2008 and December 2015, 
experienced an ICH while on anticoagulation. Patients were excluded if: the drug used for OAT was not a 
VKA; OAT indication was different from NVAF, e.g. in the presence of venous thromboembolism or 
mechanical cardiac valves. All ICH were confirmed by searching the electronical medical records of the 
Azienda Ospedaliera di Padova (GALILEO software), from which was possible to determine the site of 
bleeding, the cause (spontaneous or traumatic) and possible death (ICH was considered fatal if death 
occurred within 30 days from index date).  
For each case patient, we randomly assigned four control patients by adopting a risk-set sampling 
method defined by age (± 2 years), gender and length of warfarin administration (from initiation to the case 
index date).142 Patients’ demographics and clinical baseline information were collected for analysis from the 
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electronic records held at the Padua University Hospital and the Anticoagulation Clinic. Comorbidities like 
hypertension, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, heart disease, 
chronic kidney disease and liver disease were defined according to the corresponding guidelines and as 
requested by the specific bleeding/ischemic scores.69-72,74 Co-medications were extrapolated from 
emergency room and hospital discharge letters. The quality of anticoagulation was calculated as the time in 
the therapeutic range (TTR) from starting the treatment to the end of the follow-up, using the linear 
interpolation method devised by Rosendaal et al.31 The resulting TTR included all INR data available during 
the observation period, including when the therapy was started, and any temporary suspensions for invasive 
procedures requiring heparin bridging. Haemoglobin, platelets, creatinine and PT-INR were collected soon 
afterwards the ICH event for cases; for controls, blood test were considered if performed ± 3 months from 
the ICH date of the respective case.  Bleeding predisposition was considered present in case of:  haemoglobin 
levels persistently < 100 g/l in the 3 months before the case index date; a previous bleeding event reported 
in the medical records as a cause of hospital or emergency room admission. From the data gathered, was 
possible to calculate three of the most used bleeding scores, such as HAS-BLED,143 ATRIA,36 and ORBIT.144 The 
TE risk profile was calculated using the CHA2DS2-VASc score.14 
Results. The search retrieved 59 individuals who experienced ICH during OAT. After excluding 6 
patients because of mechanical heart valve implantation and 3 because affected by venous 
thromboembolism, the final cohort comprised 51 case patients. We randomly assign 4 controls patients for 
every case, by matching for age, gender and length of VKA therapy: thus, total control group comprises 204 
individuals.  
Table 3.2 show the characteristics related to ICH event in case patients: ICH was frequent in very 
elderly patients (especially ≥80 years of age), more than a quarter of them was fatal. As expected, 
intraparenchymal haemorrhage was often spontaneous and fatal, while subarachnoid and subdural 
bleedings were usually post-traumatic and not leading to death.  Mean INR at the time of the event was in 
target range and the median time form beginning of OAT to ICH was around 2 years, ranging from 1 year to 
51 
 
more than 4. These data seem to go against current literature which report that serious bleeding are more 
frequent in over-coagulated patients and they usually develop in the first months after initiation.145 
Table 3.2 Characteristics related to ICH event in case patients 
 Cases 
(n=51) 
Age at case index event, median (range) 
- Of which≥80 years old 
84 (78 – 87) 
37 (73%) 
Males, n (%) 24 (47%) 
Fatal ICH 
- Of which spontaneous 
- Of which post-traumatic 
14 (28%) 
10 (71%) 
4 (29%) 
Site 
- Intraparenchymal  
- Subarachnoid 
- Subdural 
 
26 (51%) 
7 (14%) 
18 (35%) 
Etiology: 
- spontaneous 
of which intraparenchymal 
of which subarachnoid 
of which subdural 
 
- post-traumatic 
of which intraparenchymal 
of which subarachnoid 
of which subdural 
 
28 (55%) 
20 (71%) 
0 
8 (29%) 
 
23 (45%) 
6 (26%) 
7 (30%) 
10 (44%) 
INR at the index event, mean ±SD  2,8 ± 0,9 
Length in months of VKA therapy from  
initiation to index event, median (range) 
26 (15 – 55) 
 
Demographic, laboratory and clinical characteristics of the case and control patients are listed in 
Table 3.3; there were no difference between groups regarding all characteristic analysed. 2 patients in the 
control group were on acenocumarol therapy, while all the rest were taking warfarin. Interestingly, TTR was 
higher, though not statistically significant, in patients who had ICH compared to controls.  Laboratory tests 
did not show any statistical significance between group. Looking at clinical characteristic, patients who 
experienced ICH had more vascular disease, more bleeding predisposition and surprisingly less ischemic 
stroke, although none of such factors did reach statistical significance. 
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Table 3.3 Cases and controls baseline characteristics  
 
Cases 
(n=51) 
Controls 
(n=204) 
p-value 
Age at case index event,  
median (range) 
84 (78 – 87) 84 (78 – 87) 
 
Males, n (%) 24 (47%) 95 (47%)  
Type of VKA: 
- Warfarin, n (%) 
- Acenocumarol, n (%) 
 
51 (100%) 
0 (0%) 
 
202 (99%) 
2 (1%) 
 
 
 
INR range: 
- 1,5 – 2,5, n (%) 
- 2 – 3, n (%) 
 
0 (0%) 
51 (100%) 
 
5 (2%) 
199 (98%) 
 
 
 
TTR in the 6 months before the case 
index event, median (range) 
70 
(45 – 90) 
64,5 
(49 – 86) 
0.43 
LABORATORY TESTS    
Haemoglobin (g/l),  
mean ± SD 
129 ± 16 131 ± 18 0.39 
Platelets (x10^9/l),  
median (range) 
217 
(188 – 258) 
219,5 
(185 – 268) 
0.98 
Creatinine (µmol/l),  
median (range) 
91 
(75 – 105) 
88 
(72 – 107) 
0.53 
CLINICAL CHARACTERISTICS   OR (I.C. 95%) 
Heart Failure, n (%) 16 (31) 53 (26) 1.30 (0.67 - 2.54) 
Blood hypertension, n (%) 44(86) 185 (91) 0.65 (0.26 - 1.63) 
Age ≥ 75 years old, n (%) 44 (86) 172 (84) 1.17 (0.48 - 2.83) 
Diabetes Mellitus, n (%) 11 (22) 38 (19) 1.20 (0.57 - 2.56) 
Stroke/TIA, n (%) 4 (8) 28 (14) 0.54 (0.18 - 1.60) 
Vascular Disease, n (%) 24 (47) 72 (35) 1.63 (0.88 - 3.03) 
Age 65 – 74 years old, n (%) 7 (14) 29 (14) 0.96 (0.40 - 2.34) 
Female Gender, n (%) 27 (53) 108 (53) 1.00 (0.54 - 1.85) 
Chronic kidney disease, n (%) 1 (2) 5 (2) 0.80 (0.09 - 6.97) 
Liver disease, n (%) 1 (4) 4 (2) 1.00 (0.11 - 9.14) 
Ischemic stroke only, n (%) 3 (6) 23 (11) 0.49 (0.14 - 1.71) 
Bleeding predisposition, n (%) 19 (37) 53 (26) 1.69 (0.89 - 3.24) 
Labile INR, n (%) 18 (35) 85 (42) 0.76 (0.40 - 1.45) 
Concomitant antiplatelet therapy, n (%) 9 (18) 38 (19) 0.94 (0.42 - 2.09) 
Anaemia, n (%) 16 (31) 65 (32) 0.98 (0.51 - 1.89) 
 
Comparing ischemic and bleeding risk scores, such as CHA2DS2-VASc, HAS-BLED, ATRIA and ORBIT, 
we did not find any statistical difference between cases and controls (table 3.4). 
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Table 3.4 Comparison of ischemic and bleeding risk scores.  
 Cases 
(n=51) 
Controls 
(n=204) 
p-value 
CHA2DS2-VASc, median (range) 4 (3 – 6) 4 (3 – 5) p=0.64 
HAS-BLED, median (range) 3 (2 – 4) 3 (2 – 3) p=0.24 
ATRIA, median (range) 4 (3 – 6) 3 (3 – 6) p=0.51 
ORBIT, median (range) 3 (1 – 3) 2 (1 – 3) p=0.43 
 
 We finally performed Receiver Operator Characteristic (ROC) Curve to evaluate the predictive value 
by comparing the C-statistics of bleeding risk scores. The determination of cut-off points for risk categories 
were adapted to our cohort to increase prediction power, using HAS-BLED=3, ATRIA=3 and ORBIT=2 as cut 
off for high bleeding risk. As shown in figure 3.2, the area under the curve of all bleeding scores was similar 
with C-statistic less than 0.6 for all of them (C-statistic for HAS-BLED, ATRIA and ORBIT were 0.55, 0.53 and 
0,54, respectively). Therefore, we concluded that none risk bleeding score had the power to accurately 
predict ICH in our cohort.  
Figure 3.2 Receiver operating characteristic curves of the risk scores. 
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3.4 Strategies to minimize the risk of bleeding 
OAT therapy is presently the most efficacious treatment for the reduction of TE in patients affected 
by NVAF. Nevertheless, OAT is associated with a significant increase of bleeding events, particularly ICH that 
may often result in deaths or severe disabling symptoms. We demonstrated in our cohort of anticoagulated 
patients that none risk factor is associated with ICH occurrence and commonly used bleeding risk scores could 
not efficaciously predict such events. However, several issues can be addressed to minimize the risk of 
haemorrhagic stroke in AF patients (Table 3.5). 
Table 3.5 Issues to be considered to minimize the risk of haemorrhagic 
stroke in anticoagulated patients with atrial fibrillation41  
Drug Selection. NOAC have proved to be as effective as warfarin in the prevention of TE in NVAF, 
with a better safety profile through the reduction of haemorrhagic strokes by approximately half. These novel 
agents should be considered in place of warfarin to ameliorate the prognosis of patients considered at higher 
risk of hemorrhagic stroke, provided that NOAC is contraindicated in severe renal or liver disease, in patients 
with mechanical heart valves and during pregnancy. 
Managing risk factors and co-morbidities. Even if new therapies greatly reduce the risk of 
haemorrhages, a careful bleeding risk assessment of NVAF patients is mandatory in order to minimize 
possible complications. Knowledge of ICH risk factors are useful in order to select patient at highest risk of 
bleeding, pursue the abolition or reduction of all correctable risk factors, take clinical decision about the 
prosecution/discontinuation of OAT and for the choice of the right agent. Blood pressure control is especially 
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important and OAT use, especially in elderly, should be as important as aggressive blood pressure 
management. Alcohol intake should be discouraged. Hepatic and renal impairment can increase bleeding 
events per se or by increasing OAT drugs concentration and therefore patients at higher risk of renal and/or 
liver deterioration should be monitored closely and therapy discontinued in presence of acute impairment. 
Discontinuation of antiplatelet therapy. Patients with stable vascular disease should not be on anti-
platelet therapy on top of OAT.146 Patients with NVAF and a previous acute coronary syndrome and/or recent 
percutaneous coronary intervention with stent application should be treated as suggested by ad-hoc 
guidelines 147,148 in order to minimize bleeding risk. In case of dual antiplatelet therapy, clopidogrel and aspirin 
should be preferred over newer anti-platelets inhibitors (such as prasugrel, ticagrelor) that demonstrated 
higher bleeding rates.  Moreover, whenever a patient taking NOAC must begin either single or dual 
antiplatelet therapy, NOAC dosage should be reduced to the lowest approved doses (i.e. dabigatran 110 mg 
bid, rivaroxaban 15 mg qd or apixaban 2.5 mg bid.). 
Patient Education. AF patients often exhibit limited knowledge of their condition and treatment. 
Indeed, some experts reported that the majority of AF patients are unaware that they are at risk of stroke.149 
Lack of knowledge presents a key barrier to uptake and adherence; several studies suggest that patients with 
greater knowledge of warfarin therapy have more often INR values within the TTR150-152 and consequently 
they have a reduced risk of treatment-associated bleeding and ischemic complications.33 Educational 
interventions seem efficacious in improving adherence and increasing TTR.151 Adherence and persistence is 
of utmost importance even during NOAC therapy and patient education is crucial. Presently there is no data 
on compliance of NOAC in everyday practice but the significance of the problem should not be 
underestimated. Patients’ knowledge about their treatment and condition should be encouraged in order to 
improve adherence, with particular stress on time adherence for patients treated with non-VKA therapy:153 
NOAC patients should be instructed to avoid taking the pills at a distance of less than 12 h for dosing bid and 
less than 24 h for the administration qd. Instructions at initiation of therapy are mandatory as group sessions 
with constant re-education at every renewal of the prescription and involvement of family. Some patients 
may prefer INR monitoring to no monitoring and there may be a preference for VKA treatment over NOAC 
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from this perspective. Prescribing clinician should be aware of limitations concerning the use of anticoagulant 
therapy, especially NOAC: some authors154 reported that many bleeding complication in patients treated with 
NOAC are probably explained by incorrect patient selection or dosage has not been adjusted based on 
patient’s characteristics. 
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4. POPULATION-BASED ANALYSIS OF ANTICOAGULATION IN VENETO REGION 
4.1 Material and methods 
Study setting. We adopted a new-user retrospective cohort design to compare patients initiating 
treatment with NOACs and VKAs. For this purpose, we performed a population-based analysis on linked 
claims data in the Veneto Region (north-eastern Italy, with about 5 million inhabitants) using: 
• The drug prescriptions archive: it includes all the prescriptions reimbursed by the National 
Health System. It holds information on purchase data, Anatomical Therapeutic Chemical 
(ATC) classification, and forms of dispensing including the number of pills per package. 
• The regional inpatients register: it includes all hospital admissions and discharge dates (both 
from private and public hospitals), and discharge diagnoses coded according to the 
International Classification of Disease, 9th Revision, Clinical Modification (ICD9-CM). 
• The database of residents registered in the regional health system: it gathers information on 
emigration status or death for any cause. 
• The archive of co-payment exemptions: it includes information on comorbidities. In Italy, 
hospital care is free while patients must contribute to out of hospital care and drug costs 
unless they are eligible for co-payment exemption because affected by specific chronic 
diseases certified by a specialist. 
All analyses were carried out on routinely collected health records submitted to an anonymization process 
allowing linkage of archives without any possibility of identification of individuals. There was no patient 
involvement in this study.  
Identification of naïve patients with NVAF. We identified all people aged 18 years or older by their 
index prescription of VKA (ATC B01AAxx) or NOACs (dabigatran B01AE07, rivaroxaban B01AF01, apixaban 
B01AF02) from July 2013, date of the first NOAC commercialization approval in Italy, to December 2015. The 
first OAC prescription, or index date, identified the date of enrolment 
in the cohort. We excluded from enrolment individuals with any dispensed prescription of OAT in the 12 
months preceding the index date. Patients with dispensed prescriptions of antiplatelet drugs post-index date 
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were also excluded. Linkage with the regional inpatients register allowed the exclusion of patients with 
mechanical heart valves, diagnosed mitral stenosis, venous thromboembolism or other indications for 
anticoagulation (adopted codes in the Table 4.1). 
Table 4.1 International Classification of Diseases 9th Revision (ICD-9CM)/Anatomical Therapeutic 
Chemical (ATC) Codes sed to identify comorbidity and co-medication 
 International Classification 
of Diseases 9th Revision 
(ICD9CM) code 
Anatomical Therapeutic 
Chemical (ATC) codes 
Co-payment 
exemption 
codes 
Deep vein thrombosis 4534; 4511; 4512; 4519; 
4532; 45181; 45183; 45189  
  
Mitral stenosis 3940   
Pulmonary embolism 415.19   
Heart valve surgery (excluding 
aortic bioprosthesis) 
35 (excluding 3521)   
    
Congestive heart failure/Left 
ventricular dysfunction** 
428 C03C 021 
Cancer 140-209  048 
Hypertension** 401-405 C02A C02B C02C  
C02DA C02L C03A C03B 
C03D C03E C03X C07C 
C07D C08G C09BA 
C09DA C09XA52 
C02DB C02DD C02DG 
C04 C05 
C07 
C07F C08 C09BB C09DB 
C09 
031 A31 
Diabetes mellitus** 250  013 
Stroke/TIA/Thromboembolism 433-438   B02 
Bleeding, History of 578; 430; 431; 432; 5997; 
7863 
  
Myocardial infarction 
410.0-410.9; 411.0; 
412;429.79 
  
Peripheral artery disease 
440.20-440.24; 440.29; 
440.30-440.32; 440.4; 
443.81; 443.89; 443.9  
  
Aortic plaque 440.0   
Abnormal renal function 582; 583; 585; 586  023 
Abnormal hepatic function 570-573; 7904  008; 016 
Outcomes    
Major bleeding 430; 431; 432; 372.72; 
362.81; 379.23; 784.7; 
511.8; 531.0 532.0 534.0 
533.0; 852.0 853.0 852.2; 
852.4; 459.0 599.7 280.0; 
531.0x, 531.2x, 531.4x, 
531.6x; 532.0x, 532.2x, 
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532.4x, 532.6x, 533.0x, 
533.2x; 533.4x, 533.6x, 
534.0x, 534.2x, 534.4x, 
534.6x; 535.01, 535.11, 
535.21, 535.31, 535.41, 
535.51; 535.61, 537.83, 
Stroke 433.x1 434.x (except sub-
code: x0), 436 
  
Medications    
Dabigatran  B01AE07  
Rivaroxaban  B01AF01  
Apixaban  B01AF02  
Warfarin  B01AA03  
Acenocoumarol  B01AA07  
Aspirin*  B01AC06  
Clopidogrel*  B01AC04  
Nonsteroidal anti-
inflammatory drugs* 
 M01A  
Alpha adrenergic blockers  C02A C02B C02C  
Nonloop diuretics 
 C02DA C02L C03A C03B 
C03D C03E C03X C07C 
C07D C08G C09BA 
C09DA C09XA52 
 
Vasodilators 
 C02DB C02DD C02DG 
C04 C05 
 
Beta-blockers  C07  
Calcium Channel blockers  C07F C08 C09BB C09DB  
Statins  C10  
Renin-angiotensin system 
inhibitors 
 C09  
*at least 3 packages 
**We identified subjects with hypertension using ICD codes, a combination treatment with at least 2 of the 
classes of antihypertensive drugs (Alpha adrenergic blockers; Nonloop diuretics; Vasodilators; Beta-
blockers; Calcium Channel blockers; Renin-angiotensin system inhibitors), and co-payment exemptions. 
Likewise, congestive heart failure individuals were identified using ICD codes, ATC codes, and co-payment 
exemptions, while diabetes using ICD and co-payment exemption codes. 
 
Patient exposure. We adopted two analytical approaches. In the intention to treat (ITT) approach, 
patients were considered as being continuously exposed from the index date until the occurrence of an 
endpoint or the end of the programmed follow up, whichever came first. In the as treated (AT) approach, 
exposure was calculated from the index date until the absence of a new prescription by the end of a 60-day 
period from the last identified index medication fill (grace time), occurrence of an endpoint, or the end of 
follow-up, whichever came first. In this setting, we measured drug exposure in terms of defined daily doses 
(DDD).155 The number of DDD was converted to the number of days the patient was treated, counting 1 DDD 
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per day and distributing all available DDDs to days of follow-up (including the days covered by the last 
prescription). The last date of enrolment was 31 December 2015 while follow up extended until 31 March 
2016 to allow a follow up of at least 3 months for all individuals.  
Baseline demographics and clinical features of patients. Demographics were recorded at the time 
of enrolment in the cohort. By linkage of drug prescriptions, inpatients records, and co-payment exemptions, 
we identified patient comorbidities and drugs of interest (as detailed in the footnote of Table 4.1). 
Comorbidities included diabetes, congestive heart failure, cerebrovascular disease, peripheral and carotid 
artery diseases, hypertension, myocardial infarction, coronary bypass graft and percutaneous coronary 
intervention, chronic renal disease, chronic liver disease, history of MB, and diagnosis of cancer. Assessed 
drugs of interest included concomitant prescription of antiplatelet agents, NSAID, and antihypertensive 
drugs. All comorbidities were used to compute propensity scores. CHA2DS2-VASc score was calculated using 
the relevant comorbidities identified through diagnoses coded in the previous 2 years before the index date. 
The bleeding risk was assessed at the time of inclusion in the cohort using a modified HAS-B(L)ED score that 
did not include labile INR. History of bleeding included diagnoses coded in the previous 10 years. 
Endpoint definition. Study endpoints were ischaemic stroke, MB including ICH, myocardial infarction 
defined according to ICD-9CM codes (Table A1), and death from any cause. We identified endpoints by 
inpatient hospital relevant primary and secondary discharge diagnoses that included ICD codes of interest. 
MB events were identified using the Cunningham algorithm for automated database definition of serious 
bleeding related to OAT use.156 A Quarantine period of 30 days was set for ischaemic stroke and myocardial 
infarction, thus events recorded in the 30 days following index date were not considered in the final 
analysis.17 For the other endpoints, we started counting the days at risk from the index date. 
Statistical analysis. We assessed the incidence of endpoints on the NOAC and VKA cohorts. To adjust 
for differences in baseline characteristics between the cohorts, two analytic methods were adopted, both 
based on propensity scores. In the first stage, multivariate logistic regression including all measured 
covariates was performed to assess the probability (propensity) of being a NOAC rather than a VKA user. In 
the second stage: i) the regression models were stratified by propensity score; ii) NOAC users were matched 
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by propensity score and semester of enrolment to VKA users in a one-to-one ratio by means of nearest 
neighbour matching within specified calliper. The rate of events for the assessed endpoints is expressed as 
number per 100 patient-years. In the ITT approach, a time to event analysis was adopted to measure the risk 
of study endpoints from the initial prescription until the occurrence of ischaemic stroke, myocardial 
infarction, MB, death, emigration, or end of follow-up (31 March 2016), whichever came first. In the AT 
approach, additional censoring events were either switch to a different anticoagulant drug or discontinuation 
of the use of an anticoagulant. 
Cox regression was used to compare event rates between treatment groups with results expressed 
as hazard ratios (HR) with 95% confidence intervals (CI). 
 
4.2 results on the total cohort 
From July 2013 (date in which NOACs were introduced in Italy) to December 2015, 137.800 
individuals newly initiated on oral anticoagulant treatment were identified. Of these, 22.896 were excluded 
mainly for heart valve surgery and venous thromboembolism. The rest were excluded because they had a 
former diagnosis of mitral stenosis and a few patients for residing outside the Veneto Region. From the 
remaining 114.904 patients, 65.737 were excluded for being prior users of VKA and 8.756 for being 
concurrent users of antiplatelet drugs. In this way, 40.411 naïve patients were identified: 6.923 treated with 
NOAC and 33.488 with VKA. The distribution of patients receiving specific NOAC agents was 33%, 41% and 
26% for dabigatran, rivaroxaban and apixaban, respectively. 
Baseline and clinical characteristics. The NOACs cohort included more female individuals, elderly, as 
well as those with previous stroke. These data translated into a higher mean CHA2DS2VASc and HASBED 
score in this group (3.23 vs 3.05 and 2.36 vs 2.19, respectively). NOAC cohort significantly differed from the 
VKAs cohort in almost all assessed characteristics. After matching by propensity score, the two cohorts were 
comparable, with 6740 individuals in each arm (Table 4.2) 
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Table 4.2 Baseline demographics and clinical characteristics of study subjects treated with NOAC or VKA 
(propensity score 1:1 match). 
Intention to treat (ITT) analysis. In the ITT analysis, follow up extended for 7.645 patient-years in the 
NOAC cohort and 47.428 patient-years in the VKA cohort. The overall crude rate of events was fairly similar 
between the groups. The rate of ischaemic stroke was quite similar among NOAC and VKA users (0.7% patient 
years and 0.6% patient years, respectively). MB rate was 1.6% patient-years in both NOAC and VKA groups. 
In the Cox regression analysis (Fig. 4.1), the relative risk of stroke did not significantly differ in the stratified 
and one-to-one matched analysis (HR 0.93; 95%CI 0.68–1.28 and HR 1.14; 95%CI 0.76–1.71, respectively). 
Moreover, the relative risk of bleeding was also not different in the stratified and one-to-one matched 
analysis (HR 0.96; 95%CI 0.78–1.17 and HR 1.07; 95%CI 0.82–1.38, respectively). However, the rate of ICH 
was significantly lower with NOAC in the stratified model (HR 0.69; 95%CI 0.48–0.99); a similar result was 
observed in the one-to-one matched analysis although not reaching statistical significance (HR 0.73; 95%CI 
0.47–1.13). The risk of death was significantly lower in the NOAC cohort using both analytical approaches 
(HR 0.83; 95%CI 0.74–0.93 and HR 0.84; 95%CI 0.73–0.97, respectively). 
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Figure 4.1 Effectiveness and safety outcomes in the ITT analysis (HR; 95%CI) with (a) stratification by 
propensity score and (b) stratification with 1:1 matching 
 
 
As Treated (AT) analysis. Follow-up extended for 6.178 patient years in the NOAC cohort, and for 
20.611 patient years in the VKAs cohort. A higher overall crude rate of MB was recorded among the VKA 
users as compared to NOAC users (2.0% patient-years and 1.5% patient-years, respectively). In Cox regression 
analysis (Figure 4.2), the relative risk of stroke did not statistically differ in the stratified and one-to-one 
matched analysis (HR 0.91; 95%CI 0.60–1.36 and HR 1.05; 95%CI 0.61–1.81, respectively). Moreover, the 
relative risk of bleeding was also not statistically different in the stratified and one-to-one matched analysis 
(HR 0.86; 95%CI 0.68–1.10 and HR 0.89; 95%CI 0.65–1.23, respectively). The rate of ICH was significantly 
lower with NOACs both in the stratified model and in the one-to-one matched analysis (HR 0.51; 95%CI 0.32–
0.80 and HR 0.52; 95%CI 0.30–0.90, respectively). The risk of death was lower with NOACs using both 
analytical approaches although not reaching statistical significance (HR 0.93; 95%CI 0.80–1.09 and HR 0.91; 
95%CI 0.75–1.09, respectively). 
Figure 4.2 Effectiveness and safety outcomes in the AT analysis (HR; 95%CI) with (a) stratification by 
propensity score and (b) stratification with 1:1 matching 
 
(a) (b) 
(a) (b) 
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Discussion. Despite the good control of anticoagulation with VKAs in our region, we found a better 
safety and equivalent effectiveness with NOAC in patients with NVAF. In this study, patients with NVAF and 
a first prescription of oral anticoagulants were selected by excluding those with venous thromboembolism, 
cardiovascular surgery, or mitral stenosis. Patient enrolment started at the time of introduction of NOACs in 
the Italian healthcare system. NOACs were preferentially started in very elderly patients (over 85 years of 
age) and in those with previous stroke. As a result, NOAC group presented a higher CHA2DS2-VASc and HAS-
BED score. The perceived advantage of NOAC in terms of safety and better manageability may account for 
the higher prescription rates in the elderly. Comparative analysis of end-points was performed using 
stratified and 1:1 matched analysis. The strategy of matching within stratum regression (stratification) 
adjustment may be used to account for residual differences between patients treated with NOAC and VKA. 
Moreover, analysis was computed according to the first prescription (ITT) or to drug exposure (AT). ITT 
analysis is more pertinent for the evaluation of effectiveness in terms of the public health impact with the 
introduction of new drugs, while in the AT we sought for treatment effect according to adherence. 
Despite the higher risk for ischaemic stroke in the NOAC group (higher CHA2DS2-VASc score), the rate 
of ischaemic events (%patient-years) was similar to that observed in VKA group. Similar results were obtained 
in the stratified and 1:1 matched analysis using both ITT and AT. These data emphasise the concept of equal 
effectiveness of NOAC versus VKA in stroke prevention in NVAF.45  The rate of MB in the VKA group is in line 
with that reported in anticoagulation clinics in Italy (2% patient-years) and stems for a good clinical and 
laboratory control of treatment in our region.66,68 Clearly, a good performance of VKA-treatment might have 
reduced the relative benefit of NOAC in terms of bleeding complications.34 However, the crude rate of MB 
was higher with VKAs in the as treated analysis (2.0% vs 1.5% patient-years), even with a well-managed VKA 
therapy. This result is further emphasised considering the lower bleeding risk in the VKA group as far as age 
and previous stroke are concerned.65,66,86,157 The propensity score analysis fully confirmed the reduction of 
ICH, already observed in the registration trials of NOAC, in both ITT and AT. The analysis of the effectiveness 
and safety of each NOAC needs larger numbers and will be the subject of a further study including more 
patients and/or with an extended follow-up.  A significant reduction in death rates with NOAC was reported 
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in at least one randomized study48 and confirmed by real world data.158 In our study, mortality was 
significantly lower in the NOACs cohort as compared to VKA users in the intention to treat approach; 
however, such finding did not reach statistical significance in the as treated analysis despite maintaining the 
same trend of reduction. This difference might be due to unaccounted reasons for therapy discontinuation. 
No difference in the incidence of myocardial infarction was observed between NOAC and VKA treated 
individuals. Despite the robust analysis, our findings have limitations related to the study's retrospective 
design and to data collected on routine health records without direct patient involvement. Furthermore, 
individual patient TTR data were not available. Nevertheless, our results have important clinical and 
healthcare policy implications when considering the observed overall benefit with NOAC over a generally 
well conducted VKA therapy as a comparator. 
In conclusion, the present analysis confirms that, despite the good control of anticoagulation with 
VKA in our region, NOAC have a better safety and equivalent effectiveness than standard anticoagulant 
therapy.  
 
4.3 results in elderly patients 
After demonstrating a good safety-efficacy profile with NOAC in the general population, we aimed to 
focus on elderly patients and their pattern of bleeding. To this end, we performed an analysis comprehending 
only patients with 80 years of age or more.  
From the 40.411 naïve patients of the global analysis, 25.275 were excluded because younger than 
80 years of age. In this way, 15.136 elderly patients affected by NVAF were identified, 2.882 with a first NOAC 
prescription and 12.254 with a first VKA prescription. Due to the reduced number of individuals, we calculate 
propensity score with only one technique (propensity score coefficient) and no 1:1 matching. ITT and AT 
analyses were both performed.  
Baseline and clinical characteristics. The NOAC cohort included more female individuals, very elderly 
(≥85 years old), as well as those with previous stroke, heart failure and history of bleeding. These data 
translated into a higher mean CHA2DS2-VASc in this group (4.3 vs 4.1, p<0.001). As expected, people with 
66 
 
chronic kidney disease were more frequently on VKA therapy, as NOAC have a relative contra-indication in 
this subset of patients (Table 4.2). After matching by propensity score, the two cohorts were comparable.  
Table 4.3 Baseline demographics and clinical characteristics of study 
elderly subjects treated with NOAC or VKA 
 NOAC VKA p-value 
Subject number 2882 12254  
Gender    
Male 37,4% 40,9% 
<0.001 
Female 62,6% 59,1% 
Age groups    
Age 80-84 years old 48,8% 55,1% 
<0.001 
Age ≥85 years old 51,2% 44,9% 
ISCHEMIC RISK SCORE    
CHA2DS2-VASc, mean±SD 4.3±1.3 4.1±1.2 <0.001 
CHA2DS2-VASc 2-3 27,8% 32,9% 
<0.001 CHA2DS2-VASc 4-5 51,1% 55,1% 
CHA2DS2-VASc 6+ 21,0% 12,0% 
COMORBIDITIES    
Congestive heart failure/Left 
ventricular dysfunction 
15,0% 17,0% <0.01 
Cancer 9,8% 9,7% n.s. 
Diabetes 17,2% 18,3% n.s. 
Stroke/TIA/Thromboembolism 26,7% 13,3% <0.001 
History of bleeding 4,2% 2,7% <0.001 
Myocardial 
 infarction 
2,7% 2,9% n.s. 
Peripheral artery disease 1,8% 2,2% n.s. 
Chronic kidney disease 4,0% 6,2% <0.001 
 
Intention to treat (ITT) analysis. In the ITT analysis, follow up extended for 3.053 patient-years in the 
NOAC cohort and 16545 patient-years in the VKA cohort. The overall crude rate of events 
(death+ischemic+bleeding) was lower in NOAC than in VKA group (13.6% patient-years and 14.8% patient-
years, respectively). The rate of ischaemic stroke was quite similar among NOAC and VKA users (1.01% 
patient-years and 0.97% patient-years, respectively). MB rate was 2.4% patient-years in NOAC users and 2.3% 
patients-year in the VKA group. Looking at the site for MB, gastrointestinal bleeding was more frequent in 
NOAC users (1.28% patients-year versus 0.77% patients-year), driven by an increase in lower and unspecified 
gastrointestinal bleedings. In the Cox regression analysis (Figure 4.3), the relative risk of stroke, myocardial 
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infarction and MB did not significantly differ between groups. There was a little but significant benefit of 
NOAC in terms of mortality (HR 0.87; 95%CI 0.77–0.99). Looking at different bleeding sites, the relative risk 
of gastrointestinal bleeding was higher with NOAC (HR 1.73; 95%CI 1.17–2.56), particularly when considering 
lower gastrointestinal bleeding only (HR 2.52; 95%CI 1.28–4.95). The hazard ratio for other bleeding sites, 
including ICH, did not reach statistical significance.    
Figure 4.3 Effectiveness and safety outcomes in the ITT analysis (HR; 95%CI)  
 
As treated (AT) analysis. In the AT analysis, follow up extended for 2.472 patient-years in the NOAC 
cohort and 6.686 patient-years in the VKA cohort. Results are consistent with the ITT analysis for all 
endopints. The overall crude rate of events (death+ischemic+bleeding) was lower in NOAC than in VKA group 
(11.8% patient-years and 13.9% patient-years, respectively). The rate of ischaemic stroke was 0.6% patient-
years in both groups. MB rate was 2.1% patient-years in NOAC users and 2.8% patients-year in the VKA group. 
Looking at the site for MB, gastrointestinal bleeding was more frequent in NOAC users (1.25% patients-year 
versus 0.9% patients-year), driven by an increase in lower and unspecified gastrointestinal bleedings, while 
ICH incidence rate was more than halved in the NOAC group (0.5% patients-year versus 1.3% patients-year). 
In the Cox regression analysis (Figure 4.4), the relative risk of death, stroke, myocardial infarction, and MB 
did not significantly differ between groups. Looking at different bleeding sites, the relative risk of 
gastrointestinal bleeding was higher with NOAC (HR 1.81; 95%CI 1.12–2.94), particularly when considering 
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lower gastrointestinal bleeding only (HR 3.48; 95%CI 1.51–8.05). On the other side, the risk of ICH was lower 
in the NOAC group (HR 0.32; 95%CI 0.16–0.65). The hazard ratio for other bleeding sites did not reach 
statistical significance.    
Figure 4.4 Effectiveness and safety outcomes in the AT analysis (HR; 95%CI)  
 
Discussion. The present analysis confirms that ageing is associated with an increase of ischemic and 
haemorrhagic complication while on OAT (stroke incidence rate of 1% patient-year in elderly versus incidence 
rate of 0.7% patient-year in total cohort; MB incidence rate of 2.8% patient-year in elderly versus incidence 
rate of 2% patient-year in total cohort). Veneto region develop a good network of Thrombosis Centres in its 
territory, therefore we may argue that VKA therapy has been well managed in this cohort. Once more, NOAC 
demonstrated a very good efficacy and safety profile even in elderly, performing equal or better than VKA in 
almost all endpoints. The only exception has been an increased risk of gastrointestinal bleedings, particularly 
from the lower tract; this may be due to the anticoagulant effect of NOAC, that is very fast and it starts from 
the site of absorption. Therefore caution should be paid in prescribing NOAC in patients prone to GI bleeding 
(previous bleeding, peptic ulcer, diverticulosis, intestinal angiodysplasia, polyps, etc.) and clinical history 
should be taken into account. However, it should be noted that total MB rate and overall mortality have not 
been affected form the increase in GI bleeding; overall NOAC benefit is therefore maintained, probably driven 
by a major reduction in ICH, which are usually more severe and disabling then GI bleedings. 
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7. CONCLUSION 
OAT is the mainstay therapy for the prevention of ischemic stroke and other TE in patients affected by 
AF.12,148,159 Standard anticoagulation is usually achieved by warfarin, a vitamin K antagonist drug that works 
by inhibiting the production of all vitamin-K dependent coagulation factors. Along with a reduction of TE, 
OAT inevitably exposes patients to the risk of bleeding events ranging from minor and self-limiting bleeds to 
fatal haemorrhages. Therefore, when clinicians prescribe these drugs, they should balance the risk of 
ischemic stroke against the risk of MB in that particular patient.  
Elderly patients have a higher risk both of bleeding and of stroke and a relevant underuse of VKA therapy 
has been reported. From our set of studies, we tried to better elucidate the risk and the benefit coming from 
warfarin use in elderly population. 
We could demonstrate that, in a real-world cohort of very elderly patients with a well-managed VKA 
therapy, the risk of complications (both haemorrhagic and ischemic) is very high and much higher than what 
reported in clinical trials. However, net clinical benefit seems preserved, meaning that the calculated risk of 
stroke without OAT remains higher than the observed risk of bleeding during OAT. 
Notwithstanding these results, discontinuation rate in these patients is very high and mainly driven by 
perceived frailty and high bleeding risk. Patients who discontinue treatment showed lower TTR, higher 
complication rates while on VKA therapy and faced a severe prognosis after discontinuation. Therefore, there 
is the need to increase OAT persistency by improving patient education and clinician knowledge or by 
switching to newer class of drugs when indicated. 
We were not able to find any evidence that suspending warfarin enhance survival; indeed, looking at 
patients who suffered a MB while on warfarin, we were able to demonstrate a worse survival at 3 years of 
patients who stop warfarin versus patients who persist on VKA. 
Haemorrhagic stroke caused by spontaneous ICH is the most fearful OAT side effect, being related to 
very high rates of mortality and disability.108 We performed a case-control study and we were not able to find 
any factor, except for age, whose exposition was connected to higher risk of ICH: these events therefore are 
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not predictable and actual bleeding risk scores are not able to select a truly high risk patients for this 
particular condition. 
The advent of non-vitamin K oral anticoagulants (NOAC), such as activated factor II (FIIa) inhibitors (i.e. 
dabigatran) and activated factor X (FXa) inhibitors (i.e. rivaroxaban, apixaban and edoxaban) widened the 
therapeutic options for TE prevention in patients with NVAF. Among many advantages, NOAC significantly 
reduce ICH. In order to confirm literature results and to evaluate the impact of NOAC in our local healthcare 
system, we performed a population-based study on Veneto Region using claim data from hospital discharge 
codes, exemptions and drugs prescription, to compare standard VKA therapy against NOAC in NVAF patients. 
Despite the good control of anticoagulation with VKA in our region, we found a better safety and equivalent 
effectiveness with NOAC, mainly driven by a a consistent reduction in ICH rates. 
Looking at the subset of patients ≥80 years old, we found a marked increase in gastrointestinal bleeding, 
especially from the lower tract, in patients treated with NOAC. However, ischemic stroke and total major 
bleedings rates were similar among the two groups and NOAC patients showed a lower risk of ICH and lower 
risk of death. Therefore, special care should be paid in the evaluation of elderly patients at increased risk of 
gastrointestinal bleeding and clinical history is to be taken into account. 
In conclusion, NOAC should be regarded as a first choice in very elderly patients with NVAF mainly 
because of reduced ICH events but also because their ease of use that may impact on drug adherence. 
Attention should be paid to contra-indication of this therapy (i.e. severe renal disease, mechanical valves, 
rheumatic disease) and to select the right dose according to patients’ characteristics. Patient education on 
the importance of OAT and the risk connected to poor adherence to therapy remains a main task of 
Thrombosis Centre.    
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